# **SYSTEMATIC REVIEW AND META-ANALYSIS**

# End-Diastolic Forward Flow and Restrictive Physiology in Repaired Tetralogy of Fallot: A Systematic Review and Meta-Analysis

Jef Van den Eynde<sup>10</sup>, BSc; Emilie Derdeyn<sup>10</sup>, BSc; Art Schuermans<sup>10</sup>; Pushpa Shivaram<sup>10</sup>, MD; Werner Budts<sup>10</sup>, MD, PhD; David A. Danford, MD; Shelby Kutty<sup>10</sup>, MD, PhD, MHCM

**BACKGROUND:** Pulmonary arterial end-diastolic forward flow (EDFF) following repaired tetralogy of Fallot has been thought to represent right ventricular (RV) restrictive physiology, but is not fully understood. This systematic review and meta-analysis sought to clarify its physiological and clinical correlates, and to define a framework for understanding EDFF and RV restrictive physiology.

**METHODS AND RESULTS:** PubMed/MEDLINE, Embase, Scopus, and reference lists of relevant articles were searched for observational studies published before March 2021. Random-effects meta-analysis was performed to identify factors associated with EDFF. Forty-two individual studies published between 1995 and 2021, including a total of 2651 participants (1132 with EDFF; 1519 with no EDFF), met eligibility criteria. The pooled estimated prevalence of EDFF among patients with repaired tetralogy of Fallot was 46.5% (95% CI, 41.6%–51.3%). Among patients with EDFF, the use of a transannular patch was significantly more common, and their stay in the intensive care unit was longer. EDFF was associated with greater RV indexed volumes and mass, as well as smaller E-wave velocity at the tricuspid valve. Finally, pulmonary regurgitation fraction was greater in patients with EDFF, and moderate to severe pulmonary regurgitation was more common in this population.

**CONCLUSIONS:** EDFF is associated with dilated, hypertrophied RVs and longstanding pulmonary regurgitation. Although several studies have defined RV restrictive physiology as the presence of EDFF, our study found no clear indicators of poor RV compliance in patients with EDFF, suggesting that EDFF may have multiple causes and might not be the precise equivalent of RV restrictive physiology.

Key Words: antegrade diastolic flow = end-diastolic forward flow = meta-analysis = restrictive physiology = tetralogy of Fallot

Tetralogy of Fallot (ToF) is the most common type of cyanotic congenital heart disease.<sup>1</sup> Although great strides have been made in the initial management of this condition, patients with repaired ToF (rToF) carry significant residual hemodynamic burden.<sup>2</sup> Long-term functional deterioration and adverse outcomes, such as arrhythmias, ventricular dysfunction, and mortality, have been related to longstanding pulmonary regurgitation (PR) and right ventricular (RV) volume overload.<sup>3,4</sup> The concept of RV restrictive physiology (RVRP) has been introduced to refer to abnormalities in RV diastolic function, which have been observed both transiently at the time of initial repair<sup>5</sup> and chronically at late follow-up.<sup>6</sup> Initial reports<sup>5–10</sup> have linked RVRP to the presence of enddiastolic forward flow (EDFF) into the pulmonary artery (ie, "antegrade diastolic pulmonary flow," "antegrade diastolic pulmonary artery flow," and "antegrade diastolic flow"). This phenomenon was thought to result from an RV so "stiff" as to be unfillable late in diastole, as a passive conduit between right atrium (RA) and pulmonary artery during atrial systole.<sup>6</sup>

Correspondence to: Shelby Kutty, MD, PhD, MHCM, Johns Hopkins Hospital and School of Medicine, 1800 Orleans St, Baltimore, MD 21287. E-mail: skutty1@ihmi.edu

Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.121.024036

For Sources of Funding and Disclosures, see page 13.

<sup>© 2022</sup> The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

JAHA is available at: www.ahajournals.org/journal/jaha

## **CLINICAL PERSPECTIVE**

#### What Is New?

- In this systematic review and meta-analysis of 2651 patients with repaired tetralogy of Fallot from 42 individual studies, end-diastolic forward flow (EDFF) occurred in 46.5%.
- EDFF was associated with transannular patch repair, greater right ventricular indexed volumes and mass, smaller E-wave velocity at the tricuspid valve, increased rates of moderate to severe pulmonary regurgitation, and longer stay in the intensive care unit.

#### What Are the Clinical Implications?

- Although often used as a surrogate marker of right ventricular restrictive physiology, EDFF may have multiple alternative causes and might not be the precise equivalent of right ventricular restrictive physiology.
- Our review supports a specific reconciliation of the conflicting EDFF literature, based on the presence of 2 main phenotypes: (1) early-onset, "primary" EDFF and (2) late-onset, "secondary" EDFF; the latter has become more prevalent in contemporary practice, with improved perioperative ventricular diastolic function but progressive dilatation resulting from longstanding pulmonary regurgitation.
- Future studies should refine the diagnostic criteria for right ventricular restrictive physiology and clarify the potential prognostic relevance of EDFF in various settings.

#### Nonstandard Abbreviations and Acronyms

EDFF	end-diastolic forward flow
MD	mean difference
PR	pulmonary regurgitation
RA	right atrial
rToF	repaired tetralogy of Fallot
RVEDVi	right ventricular end-diastolic volume indexed
RVRP ToF	right ventricular restrictive physiology tetralogy of Fallot

RVRP has been identified on the basis of the presence of EDFF on Doppler echocardiography or cardiac magnetic resonance (CMR), but studies of its physiological and clinical correlates have yielded divergent results. Some authors have suggested that RVRP is beneficial because it decreases PR, RV dilatation, and QRS duration, resulting in improved exercise capacity and lower risk of ventricular arrhythmias.<sup>6–8</sup> Others, in contrast, have found more severe PR, larger RV volumes, and worse exercise capacity in patients with EDFF.<sup>5,11–15</sup> On the basis of simultaneous catheter pressure monitoring, EDFF can occur whenever RV diastolic pressure equals or exceeds pulmonary artery pressure.<sup>16</sup> An insight emerges that EDFF might not always carry the same implications as true RVRP. The current understanding of the relationship among the various factors leading to EDFF and RVRP remains incomplete. The purpose of this meta-analysis is to clarify the physiological and clinical correlates of EDFF, and to establish a framework to guide current thinking about EDFF and RVRP.

#### METHODS

Data used for the analyses in this article will be made available from the corresponding author on reasonable request.

# Eligibility Criteria, Databases, and Search Strategy

We followed 2 internationally recognized protocols: Preferred Reporting Items for Systematic Reviews and Meta-Analysis<sup>17</sup> and Meta-Analysis of Observational Studies in Epidemiology.<sup>18</sup> Studies were included if (1) the population consisted of patients with ToF, (2) patients had undergone full ToF repair by the time of evaluation, (3) patient characteristics, surgical history, hemodynamic parameters, and/or other measurements were compared between patients with EDFF and those without, and (4) studies were prospective or retrospective observational studies or randomized controlled trials. Exclusion criteria included the following: (1) nonoriginal articles, such as review articles, meta-analyses, guidelines, consensus statements, conference abstract, editorials, letters, and book reviews, (2) in vitro or in vivo preclinical research, or (3) publications did not include data on EDFF status.

Databases were searched for articles meeting our inclusion criteria and published by March 8, 2021: PubMed/MEDLINE, Embase, Scopus, and reference lists of relevant articles. The detailed search terms that were used for this search are given in Data S1. The following steps were taken: (1) identification of titles of records through databases searching, (2) removal of duplicates, (3) screening and selection of abstracts, (4) assessment for eligibility through full-text articles, and (5) final inclusion in the study. Studies were selected by 2 independent reviewers (J.V.D.E. and E.D.). Discrepancies were resolved by consensus.

#### **Data Items**

All variables that were compared between EDFF and no EDFF groups in least 2 studies were included in the

meta-analysis. These variables included patient characteristics, surgical history, hemodynamic parameters, and other measurements. For studies reporting interquartile ranges, the mean was estimated according to a well-accepted and commonly used formula.<sup>19</sup> Two reviewers independently extracted the data (J.V.D.E. and E.D.). Discrepancies were resolved by consensus. From each study, we extracted first authors' name, year of publication, country of origin, study design, years of enrollment, sample size, EDFF prevalence, mean age at initial ToF repair, mean interval between ToF repair and assessment, and mean age at assessment.

#### **Statistical Analysis**

Mean differences (MDs) with 95% CI and P values were calculated for continuous variables. For binary variables, odds ratios (ORs) with 95% CI and P values were considered. I<sup>2</sup>, describing the percentage of total variation across studies that is attributable to heterogeneity rather than chance, was calculated to assess the degree of statistical heterogeneity, and its accompanying P value was obtained using the  $\chi^2$  test of the Cochran Q heterogeneity statistic.<sup>20</sup> The MD and OR were combined across the studies using a random-effects method (DerSimonian and Laird inverse variance).<sup>21</sup> The choice for randomeffects models was made on the basis of the assumption that the effect sizes in the individual studies represented samples from a mixing distribution. In addition, the results were reanalyzed using fixed-effects models to explore whether this yielded differences on the summary inferences. Forest plots were used to visualize the individual study and summary effect estimates. These analyses were conducted using the "metacont" and "metabin" functions of the R package "meta" (version 4.19-0). Funnel plots were produced for visual representation of publication bias, and were analyzed quantitatively by Begg and Mazumdar's rank correlation method<sup>22</sup> and Egger's linear regression method, using the "funnel" and "metabias" functions of the R package "meta" (version 4.19-0).<sup>23</sup> The proportions of patients who had EDFF were pooled into a global estimated prevalence using the same randomeffects method (DerSimonian and Laird inverse variance) as described above, via the "metaprop" function of the R package "meta" (version 4.19-0).

Subgroup analyses were conducted on the basis of study design (retrospective or prospective), by specifying this grouping variable in the "metacont" and "metabin" functions of the R package "meta" (version 4.19-0). Furthermore, meta-regression analyses were performed to determine whether the association of EDFF with the studied variables was modulated by (1) mean year of enrollment, (2) RV end-diastolic volume indexed (RVEDVi), (3) age at evaluation, or (4) interval from initial repair to evaluation. The regression coefficient describes how the association of EDFF with these variables differs with an increase in each of these variables. These analyses were done using the "metareg" function of the R package "meta" (version 4.19-0). No attempts were made to correct for multiple testing, given the exploratory nature of this study. All analyses were completed with R Statistical Software (version 4.0.5; Foundation for Statistical Computing, Vienna, Austria).

#### RESULTS

#### **Study Selection and Characteristics**

A total of 552 citations were identified, of which 83 publications were potentially relevant and retrieved as full text. Forty-five reports<sup>5–8,11–16,24–58</sup> of 42 individual studies fulfilled our eligibility criteria (Figure 1). Characteristics of each study and its participants are shown in Table 1. A total of 2651 participants (EDFF: 1132 participants; no EDFF: 1519 participants) were included from studies published between 1995 and 2021. All studies were nonrandomized observational studies, except for one randomized controlled trial.<sup>26,36</sup> The pooled mean age of participants was 16.5 years (39 studies, with 2323 participants) at the time of evaluation and 3.37 years (30 studies, with 2175 participants) at initial ToF repair. The interval between initial repair and evaluation was 13.0 years (21 studies, with 1421 participants).

#### Synthesis of Results *Prevalence of EDFF*

Overall, the pooled estimated prevalence of EDFF among patients with rToF was 46.5% (95% CI, 41.6%-51.3%; I<sup>2</sup>=80.9%). The reported prevalence in the 10 studies that used CMR to define EDFF (51.9%; 95% Cl, 42.4%-61.1%; I<sup>2</sup>=70.5%) tended to be marginally higher than that in the 32 studies that defined EDFF based on Doppler echocardiography (45.6%; 95% Cl, 40.2%-51.1%; I<sup>2</sup>=80.7%), although this difference did not reach statistical significance (test for subgroup differences: P=0.263). Subanalyses according to study design revealed that a higher prevalence was reported in prospective studies (49.3%; 95% CI, 42.9%-55.6%; I<sup>2</sup>=81.2%) than in retrospective studies (40.3%; 95%) Cl, 35.1%-45.6%; I2=72.9%) (test for subgroup differences: P=0.034). Meta-regression analysis revealed that the prevalence of EDFF increased with increasing RVEDVi (regression coefficient, 0.017; 95% Cl, 0.001-0.034; P=0.049; 24 studies). Other analyses revealed no significant findings.

#### Meta-Analysis

The results of the meta-analysis comparing variables between rToF patients with EDFF and those without



**Figure 1.** Flow diagram of studies included in data search. EDFF indicates end-diastolic forward flow.

are summarized in Table 2. The accompanying forest plots are given in Figures S1 through S14. The use of a transannular patch was significantly more common among patients with EDFF (random-effects model: OR, 1.98; 95% CI, 1.26–3.11; P=0.005), and intensive care unit length of stay for these patients was longer (random-effects model: MD, 4.34 days; 95% CI, 1.38–7.29 days; P=0.019) when compared with those having no EDFF.

EDFF was found to be associated with dilated RVs, as reflected by a greater RVEDVi (random-effects model: MD, 14.7 mL/m<sup>2</sup>; 95% Cl, 4.57–24.8 mL/m<sup>2</sup>; *P*=0.007), greater RV end-systolic volume indexed (random-effects model: MD, 16.1 mL/m<sup>2</sup>; 95% Cl, 1.01–31.3 mL/m<sup>2</sup>; *P*=0.039), and greater RV stroke volume indexed (random-effects model: MD, 9.57 mL/m<sup>2</sup>; 95% Cl, 0.67–18.5 mL/m<sup>2</sup>; *P*=0.040). Correspondingly, RV mass indexed was greater in patients with EDFF

(random-effects model: MD, 2.87 g/m<sup>2</sup>; 95% Cl, 0.14– 5.61 g/m<sup>2</sup>; *P*=0.042).

Furthermore, E-wave velocity at the tricuspid valve was smaller in patients with EDFF (random-effects model: MD, –11.6 cm/s; 95% Cl, –20.9 to –2.32 cm/s; P=0.019). Last, the PR fraction was greater in patients with EDFF (random-effects model: MD, 12.7%; 95% Cl, 8.91%–16.4%; P<0.001), and moderate to severe PR was more common in this population (random-effects model: OR, 1.27; 95% Cl, 1.09–1.48; P=0.021). No other significant associations with EDFF were found (Table 2).

Funnel plot analysis disclosed asymmetry around the axis for transannular patch repair, RA volume indexed, PR duration, and A-wave velocity at the tricuspid valve (Figure S15). Consequently, publication bias related to these outcomes cannot be excluded. No publication biases were found in the other short-term outcomes.

Table 1. Study and Pa	tient Characteri	stics							
Study	Country of origin	Study design	Years of enrollment	Sample size, N	Imaging tool used to define EDFF	EDFF prevalence, n/ total (%)	Mean age at initial ToF repair, y	Mean interval between ToF repair and assessment, y	Mean age at assessment, y
Aburawi 2014 <sup>24</sup>	Sweden	Prospective	NR	20	CMR	9/20 (45.0)	NR	NR	10.2
Ahmad 2012 <sup>15</sup>	Canada	Retrospective	2008-2010	112	Doppler echocardiography	58/112 (51.8)	0.0	RN	12.9
Apitz 2010 <sup>25</sup>	Germany	Prospective	NR	25	CMR	8/25 (32.0)	NR	7.1	17.9
Babu-Narayan 2012 <sup>28</sup> (overlap with Krupickova 2018)	United Kingdom	Prospective	2002-2005	64	Doppler echocardiography	27/64 (42.2)	6.0	25.1	30.1
Bonello 2013 <sup>27</sup>	United Kingdom	Prospective	2002-2008	148	Doppler echocardiography	38/148 (25.7)	4.8	RN	32.1
Cardoso 2003 <sup>28</sup>	Brazil	Prospective	2000	30	Doppler echocardiography	19/30 (63.3)	3.0	3.2	8.7
Chaturvedi 1999 <sup>29</sup>	United Kingdom	Prospective	R	11	Doppler echocardiography	4/11 (36.4)	NR	NR	1.7
Cheng 2019 <sup>30</sup>	United States	Retrospective	1999–2014	38	CMR	15/38 (39.5)	NR	NR	13.2
Cheung 2003 <sup>31</sup>	Australia	Prospective	1981–1990	45	Doppler echocardiography	24/45 (53.3)	2.1	12.5	15.0
Choi 2008 <sup>32</sup>	Korea	Retrospective	1997–2000	43	Doppler echocardiography	15/43 (34.9)	2.1	5.4	4.8
Clark 1995 <sup>33</sup> (overlap with Gatzoulis 1995)	United Kingdom	Prospective	1958–1979	30	Doppler echocardiography	18/30 (60.0)	RN	21.8	27.8
Cullen 1995 <sup>5</sup>	United Kingdom	Prospective	1992–1993	35	Doppler echocardiography	17/35 (48.6)	NR	NR	1.9
Eroglu 1999 <sup>8</sup>	Turkey	Prospective	1986–1996	44	Doppler echocardiography	25/44 (56.8)	4.0	NR	7.7
Gatzoulis 1995 <sup>6</sup> (overlap with Clark 1995)	United Kingdom	Prospective	1958–1979	38	Doppler echocardiography	20/38 (52.6)	5.2	NR	28.8
Gatzoulis 1998 <sup>34</sup> (overlap with Norgard 1996)	United Kingdom	Retrospective	1985-1994	92	Doppler echocardiography	36/92 (39.1)	RN	4.5	14.7
Helbing 1996 <sup>11</sup>	The Netherlands	Prospective	NR	19	Doppler echocardiography	13/19 (68.4)	1.5	10.0	12.0
Kordybach-Prokopiuk 2018 <sup>35</sup>	Poland	Prospective	NR	83	Doppler echocardiography	16/83 (19.3)	11.9	21.6	31.5
Krupickova 2018 <sup>36</sup> (overlap with Babu- Narayan 2012)	United Kingdom	Prospective	2002-2005	64	Doppler echocardiography	26/64 (40.6)	6.1	25.1	31.1
Kutty 2018 <sup>37</sup>	United States	Retrospective	2005–2012	399	Doppler echocardiography	122/399 (30.6)	1.1	18.5	20.5

Van den Eynde et al

(Continued)

Mean age at assessment, y	13.3	13.0	35.0	21.0	NR	14.2	12.7	15.7	4.4	10.2	14.7	NR	NR	1.6	35.0	6.7	5.0	16.3	2.2	26.5	2.5
Mean interval between ToF repair and assessment, y	12.1	NR	NR	NR	NR	NR	NR	NR	RN	9.2	NR	1.8	1.8	R	NR	NR	NR	14.0	NR	20.2	NR
Mean age at initial ToF repair, y	1.3	1.3	11.0	2.8	3.0	NR	0.4	3.1	0.7	1.0	11.5	5.9	5.6	1.6	7.7	NR	R	1.4	NR	NR	RN
EDFF prevalence, n/ total (%)	15/53 (28.3)	33/50 (66.0)	40/59 (67.8)	31/51 (60.8)	77/178 (43.3)	43/99 (43.4)	77/88 (87.5)	23/62 (37.1)	13/47 (27.7)	16/31 (51.6)	36/92 (39.1)	16/34 (47.1)	10/32 (31.3)	4/18 (22.2)	16/20 (80.0)	52/80 (65.0)	24/50 (48.0)	12/29 (41. 4)	28/50 (56.0)	18/30 (60.0)	8/23 (34.8)
Imaging tool used to define EDFF	CMR	CMR	CMR	CMR	CMR	Doppler echocardiography	Doppler echocardiography	Doppler echocardiography	Doppler echocardiography	Doppler echocardiography	Doppler echocardiography	Doppler echocardiography	Doppler echocardiography	Doppler echocardiography	Doppler echocardiography	Doppler echocardiography	Doppler echocardiography	Doppler echocardiography	Doppler echocardiography	CMR	Doppler echocardiography
Sample size, N	53	50	59	51	178	66	88	62	47	31	92	34	32	18	20	80	20	29	50	30	23
Years of enrollment	2007-2011	2007-2009	2008-2009	2007–2010	1997–2011	NR	NR	2009–2016	1985–1996	NR	1985–1994	1992–1995	1992–1995	NR	2009–2012	2001–2003	2004–2005	2008-2009	2017–2018	2015-2016	NR
Study design	Retrospective	Retrospective	Prospective	Prospective	Retrospective	Retrospective	Prospective	Retrospective	Prospective	Prospective	Retrospective	Prospective	Prospective	Prospective	Prospective	Prospective	Prospective	Prospective	Prospective	Prospective	Prospective
Country of origin	Germany	Canada	United States	The Netherlands	United States	United States	United States	Japan	United Kingdom	Sweden	United Kingdom	United Kingdom	United Kingdom	United Kingdom	Spain	Australia	India	United States	China	Iran	United Kingdom
Study	Latus 2013 <sup>38</sup>	Lee 2013 <sup>39</sup>	Lu 2010 <sup>12</sup>	Luijnenburg 2013 <sup>40</sup>	Maskatia 2013 <sup>41</sup>	Maskatia 2015 <sup>42</sup>	Mercer-Rosa 2018 <sup>43</sup>	Mori 2017 <sup>16</sup>	Munkhammar 1998 <sup>44</sup>	Munkhammar 2013 <sup>45</sup>	Norgard 1996 <sup>46</sup> (overlap with Gatzoulis 1998)	Norgard 1998 <sup>7</sup> (early restriction)	Norgard 1998 <sup>7</sup> (late restriction)	Peng 2012 <sup>47</sup>	Pijuan-Domenech 2014 <sup>48</sup>	Rathore 2006 <sup>49</sup>	Sachdev 2006 <sup>50</sup>	Samyn 2013 <sup>13</sup>	Sandeep 2019 <sup>51</sup>	Sani 2020 <sup>52</sup>	Shekerdemian 1999 <sup>53</sup>

Table 1. Continued

J Am Heart Assoc. 2022;11:e024036. DOI: 10.1161/JAHA.121.024036

(Continued)

Study	Country of origin	Study design	Years of enrollment	Sample size, N	Imaging tool used to define EDFF	EDFF prevalence, n/ total (%)	Mean age at initial ToF repair, y	Mean interval between ToF repair and assessment, y	Mean age at assessment, y
Shin 2016 <sup>54</sup>	Korea	Retrospective	2005–2015	116	Doppler echocardiography	35/116 (30.2)	2.3	14.2	NR
Sjöberg 2018 <sup>55</sup>	Sweden	Prospective	NR	15	CMR	10/15 (66.7)	NR	NR	29.0
Tominaga 2021 <sup>56</sup>	Japan	Retrospective	2003–2019	46	Doppler echocardiography	23/46 (50.0)	3.4	31.0	37.0
van den Berg 2007 <sup>14</sup>	The Netherlands	Prospective	2002-2004	36	Doppler echocardiography	24/36 (66. 7)	0.0	15.3	16.0
Vukomanovic 2006 <sup>57</sup>	Serbia and Montenegro	Prospective	1995–2004	60	Doppler echocardiography	18/60 (30.0)	4.3	R	0.6
Xu 2014 <sup>58</sup>	China	Retrospective	2011-2012	80	Doppler echocardiography	30/80 (37.5)	1.2	R	1.2
CMR indicates cardiac mé	agnetic resonance; ED	)FF, end-diastolic fc	prward flow; NR, not	t reported; an	d ToF, tetralogy of Fallot				

#### Sensitivity Analysis

The results of the fixed-effects models were largely comparable to those from random-effects models, with numerical effect estimates having the same direction and lying close to one another (Figures S1 through S14). However, because of its narrower Cls. the fixed-effects model additionally suggested a significant association with EDFF for the following variables: younger age at repair (fixed-effects model: MD, -0.07 years; 95% Cl, -0.11 to -0.02 years; P=0.004), older age at study (fixed-effects model: MD, 0.33 years; 95% Cl, 0.04-0.61 years; P=0.024), previous RV-pulmonary artery shunt (fixed-effects model: OR, 0.35; 95% Cl, 0.21-0.60; P<0.001), longer aortic cross-clamp time (fixed-effects model: MD, 6.91 minutes; 95% Cl, 4.00-9.82 minutes; P<0.001), longer cardiopulmonary bypass time (fixed-effects model: MD. 8.94 minutes: 95% Cl. 4.17-13.71 minutes; P<0.001), outflow patch repair (fixedeffects model: OR, 0.31; 95% Cl, 0.13-0.72; P=0.006), higher RV ejection fraction (fixed-effects model: MD, 3.91%; 95% Cl, 3.65%-4.18%; P<0.001), higher RV enddiastolic pressure (fixed-effects model: MD. 0.97 mm Ha: 95% Cl, 0.46-1.47 mm Hg; P=0.006), smaller left ventricular (LV) end-diastolic volume indexed (fixed-effects model: MD, -4.15 mL/m<sup>2</sup>; 95% Cl, -4.86 to -3.44 mL/ m<sup>2</sup>; P<0.001), smaller LV end-systolic volume indexed (fixed-effects model: MD, -2.97 mL/m<sup>2</sup>: 95% Cl, -3.43 to -2.52 mL/m<sup>2</sup>; P<0.001), smaller LV stroke volume indexed (fixed-effects model: MD, -1.65 mL/m<sup>2</sup>; 95% Cl, -2.05 to -1.24 mL/m<sup>2</sup>; P<0.001), greater LV ejection fraction (fixed-effects model: MD, 0.64%; 95% Cl, 0.23%-0.85%; P<0.001), greater RA area indexed (fixed-effects model: MD, 0.58 cm<sup>2</sup>/m<sup>2</sup>; 95% Cl, 0.42–0.74 cm<sup>2</sup>/m<sup>2</sup>; P=0.028), smaller E-wave deceleration at the tricuspid valve (fixedeffects model: MD, -8.62 cm/s; 95% Cl, -11.0 to -6.27 cm/s; P<0.001), greater A-wave velocity at the tricuspid valve (fixed-effects model: MD, 2.92 cm/s; 95% Cl, 0.82-5.03 cm/s; P=0.007), smaller E/A (ratio between early (E) and late atrial (A) ventricular filling velocity) at the tricuspid valve (fixed-effects model: MD, -0.09; 95% Cl, -0.17 to -0.02; P=0.016), longer PR duration (fixed-effects model: MD, 10.3 ms; 95% Cl, 8.68-12.1 ms; P<0.001), shorter QRS duration (fixed-effects model: MD, -2.90 ms; 95% Cl, -4.26 to -1.54 ms; P<0.001), higher brain natriuretic peptide levels (fixed-effects model: MD, 11.0 pg/mL; 95% Cl, 6.53-15.5 pg/mL; P<0.001), and higher NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels (fixedeffects model: MD, 61.1 pg/mL; 95% Cl, 15.2-107 pg/mL; P=0.009). Because these findings were not confirmed by both models, these should be interpreted with caution.

#### Subgroup Analyses and Meta-Regression Analyses

In an attempt to explain sources of heterogeneity and to further investigate the underlying mechanisms of EDFF in rToF, subgroup analyses and meta-regression

**Fable 1.** Continued

#### Table 2. Meta-Analysis of EDFF in rToF: Summary of Results

		Summary mea	sures		Heterogene	ity
Variable	Studies, N	OR/MD	95% CI	P value	I², %	χ <sup>2</sup> P value
Patient characteristics			1			
Age at repair, y	16	0.329	-0.419 to 1.077	0.363	95.2	<0.001
Time of follow-up since repair, y	9	0.318	-0.654 to 1.290	0.472	82.8	<0.001
Age at study, y	24	0.769	-0.080 to 1.617	0.074	90.2	<0.001
Surgical history		1	1			
Previous RVPA shunt	3	0.365	0.122 to 1.091	0.058	0	0.423
Previous BT shunt	10	0.865	0.620 to 1.205	0.347	0	0.960
Aortic cross-clamp time, min	7	7.786	-1.053 to 16.624	0.075	78.7	<0.001
CPB time, min	7	5.962	-12.243 to 24.166	0.454	88.0	<0.001
Transatrial repair	4	0.474	0.100 to 2.233	0.223	1.9	0.383
Transannular patch repair	21	1.983	1.264 to 3.112	0.005*	55.9	0.001
Outflow patch repair	4	0.323	0.095 to 1.099	0.061	0	0.520
ICU length of stay, d	4	4.339	1.384 to 7.294	0.019*	75.2	0.007
Hemodynamics						
RVEDVi, mL/m <sup>2</sup>	16	14.706	4.572 to 24.840	0.007*	91.0	<0.001
RVESVi, mL/m <sup>2</sup>	11	16.146	1.012 to 31.280	0.039*	94.9	<0.001
RVSVi, mL/m <sup>2</sup>	6	9.570	0.674 to 18.466	0.040*	98.3	<0.001
RVMi, g/m <sup>2</sup>	7	2.873	0.139 to 5.606	0.042*	93.9	<0.001
RVEF, %	12	-0.555	-2.640 to 1.530	0.570	95.7	<0.001
RVEDP, mm Hg	4	1.216	-0.293 to 2.724	0.083	75.8	0.006
RVESP, mm Hg	5	0.824	-5.563 to 7.210	0.738	69.9	0.010
LVEDVi, mL/m <sup>2</sup>	5	0.005	-6.334 to 6.344	0.998	87.7	<0.001
LVESVi, mL/m <sup>2</sup>	2	-1.728	-27.074 to 23.618	0.546	57.3	0.126
LVSVi, mL/m <sup>2</sup>	2	-1.179	-12.443 to 10.086	0.411	91.9	<0.001
LVEF, %	9	-0.195	-1.256 to 0.866	0.682	74.3	<0.001
RAAi, cm²/m²	3	1.083	-0.319 to 2.484	0.080	92.8	<0.001
RAVi, mL/m <sup>2</sup>	3	4.863	-10.111 to 19.836	0.297	79.4	0.008
E-wave velocity at the tricuspid valve, cm/s	11	-11.586	-20.850 to -2.321	0.019*	79.3	<0.001
E-wave duration at the tricuspid valve, ms	4	-7.077	-33.700 to 19.545	0.460	85.3	<0.001
E-wave deceleration at the tricuspid valve, ms	8	-14.507	-34.448 to 5.434	0.129	91.5	<0.001
A-wave velocity at the tricuspid valve, cm/s	10	-1.204	-5.682 to 3.274	0.558	76.2	<0.001
A-wave duration at the tricuspid valve, ms	2	-15.546	-174.249 to 143.158	0.431	5.4	0.304
E/A at the tricuspid valve	10	-0.106	-0.246 to 0.033	0.119	59.5	0.008
E' at the tricuspid valve, cm/s	2	0.914	-12.862 to 14.690	0.554	73.4	0.053
A' at the tricuspid valve, cm/s	2	0.000	0.000 to 0.000	N/A	0	1.000
E/E' at the tricuspid valve	2	-0.893	-2.161 to 0.374	0.071	0	0.802
Moderate to severe PR	3	1.268	1.090 to 1.476	0.021*	0	0.982
PR fraction, %	8	12.662	8.912 to 16.411	<0.001*	56.3	0.025
PR duration, ms	7	-46.569	-100.462 to 7.323	0.079	95.1	<0.001
Other						
QRS duration, ms	18	4.983	-4.296 to 14.262	0.272	89.9	<0.001
BNP, pg/mL	3	13.264	-10.052 to 36.581	0.134	66.8	0.049
NT-proBNP, pg/mL	3	61.125	-25.398 to 147.647	0.093	0	0.479
Peak VO <sub>2</sub> , %	7	8.433	-0.050 to 16.916	0.051	87.5	<0.001
Peak VO <sub>2</sub> , mL/kg per min	6	0.648	-3.857 to 5.153	0.727	98.0	<0.001

A' indicates annulus velocity during late atrial filling; BNP, brain natriuretic peptide; BT, Blalock-Taussig; CPB, cardiopulmonary bypass; E', annulus velocity during early filling; E/A, ratio between early (E) and late atrial (A) ventricular filling velocity; EDFF, end-diastolic forward flow; ICU, intensive care unit; LVEDVi, left ventricular end-diastolic volume indexed; LVEF, left ventricular ejection fraction; LVESVi, left ventricular end-systolic volume indexed; LVSVi, left ventricular stroke volume indexed; MD, mean difference; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OR, odds ratio; PR, pulmonary regurgitation; RAAi, right atrial area indexed; RAVi, right atrial volume indexed; rToF, repaired tetralogy of Fallot; RVEDP, right ventricular end-diastolic pressure; RVESVi, right ventricular end-diastolic volume indexed; RVEF, right ventricular ejection fraction; RVESP, right ventricular end-systolic pressure; RVESVi, right ventricular end-systolic volume indexed; RVEH, right ventricular ejection fraction; RVESP, right ventricular end-systolic pressure; RVESVi, right ventricular end-systolic volume indexed; RVEH, right ventricular end-diastolic pressure; RVESVi, right ventricular end-systolic volume indexed; RVEH, right ventricular mass indexed; RVEA, right ventrice–pulmonary artery; RVSVi, right ventricular stroke volume indexed; and VO<sub>2</sub>, oxygen consumption. \**P*<0.05.



Figure 2. Summary of the main findings about end-diastolic forward flow (EDFF) in repaired tetralogy of Fallot (rToF) in the present meta-analysis.

ICU indicates intensive care unit; PR, pulmonary regurgitation; and RV, right ventricular.

analyses were performed. The findings of these analyses are presented in Data S1.

#### DISCUSSION

#### Summary of Evidence

The current meta-analysis summarizes the available evidence on associations of EDFF with patient characteristics, hemodynamic findings, and surgical properties in patients with rToF. Our findings, summarized in Figure 2, are as follows: (1) EDFF occurred in 46.5% of all patients. (2) the use of a transannular patch was significantly more common among patients with EDFF, (3) intensive care unit length of stay for these patients was longer, (4) EDFF was associated with greater RV indexed volumes and mass, as well as smaller E-wave velocity at the tricuspid valve, and (5) PR fraction was greater, and moderate to severe PR was more common with EDFF. Overall, these results suggest that EDFF is associated with dilated, hypertrophied RVs experiencing longstanding PR. However, as no clear indicators of poor RV compliance were found, EDFF may have multiple causes and might not correspond precisely with RVRP.

#### EDFF Is Not a Specific Marker of RVRP and May Occur Under Several Other Conditions

Ever since the initial reports on EDFF,<sup>5–10</sup> it has been regarded as a hallmark feature of RVRP. Indeed, studies conducted thereafter, which were included in the present meta-analysis, defined RVRP solely based on the presence of EDFF. Strictly speaking, however, restrictive physiology implies poor ventricular compliance, or its reciprocal increased myocardial stiffness, which may be either a manifestation of primary cardiomyopathy or secondary to other cardiovascular diseases.<sup>59</sup> The gold standard measure of LV myocardial stiffness is the slope of the end-diastolic pressure-volume relationship,<sup>60</sup> but is less practical for the RV, given the trapezoidal nature of the normal RV pressure-volume relationship. Furthermore, a prerequisite of pressurevolume analysis is a closed system, meaning that the semilunar valve should be closed such that changes within the ventricle reflect muscle mechanics. As the right heart is a low-pressure system, RA pressures can at times exceed pulmonary artery pressures, promoting transmission of RA outflow into the pulmonary arteries and thus opening the system. Nonetheless, when this antegrade diastolic pulmonary artery flow occurs, it suggests that the resistance to RV filling is greater than the resistance to pulmonary artery filling; this concept has been the rationale for using EDFF as a surrogate for RVRP.61

EDFF is a convenient marker that is readily available from conventional Doppler echocardiography or CMR. However, there are several limitations to its value for diagnosis of RVRP, because other factors may modulate EDFF (Table 3).<sup>62</sup> For example, the absence of atrial systole and other conditions that decrease preload

#### Table 3. Framework to Think About Factors Influencing EDFF

Factor	Main findings
Atrial contractility	<ul> <li>Morbidity related to atrial arrhythmias is 3-fold more common among patients with EDFF, further interfering with hemodynamics<sup>27</sup></li> <li>Increased RA pressure can lead to EDFF, although EDFF can also occur in patients with low pulmonary diastolic pressure and normal RA pressure<sup>16</sup></li> </ul>
RV volumes	<ul> <li>EDFF most commonly occurs at the ends of the spectrum of RVEDVi (at ≤115 and ≥200 mL/m<sup>2</sup>), supporting the hypothesis that 2 distinct phenotypes might exist<sup>39</sup></li> </ul>
RV compliance and diastolic function	<ul> <li>Acute EDFF in the postoperative setting is associated with greater myocardial injury and oxidative stress<sup>29</sup></li> <li>The slope of the end-diastolic pressure-volume relationship is increased in EDFF, indicating increased diastolic RV stiffness<sup>25</sup></li> <li>Peak diastolic strain rate is decreased at the interventricular septum but increased at the RV free wall of patients with EDFF<sup>13,35</sup></li> <li>In a porcine model, EDFF only occurred if PR was accompanied by RV hypertrophy, supporting the role of the latter in the pathophysiology of EDFF<sup>62</sup></li> <li>Fibrosis of the RVOT is associated with EDFF and correlated with the degree of PR and RV volumes<sup>45</sup></li> </ul>
Myocardial perfusion	<ul> <li>EDFF is associated with increased basal coronary flow, probably because of increased systolic workload against a stiff fibrotic myocardium and increased RV volumes. This might, in turn, explain the decreased coronary flow reserve and impaired exercise capacity<sup>24</sup></li> </ul>
Ventricular-ventricular interactions	<ul> <li>LA size was larger and pulmonary venous flow reversals were more pronounced in patients with EDFF, suggesting increased LV filling pressures. This might be attributable to septal flattening, the induction of LV fibrosis, and/or interventricular diastolic dyssynchrony in the setting of progressive RV dilatation<sup>15</sup></li> <li>The ACE inhibitor ramipril led to an improvement in both LA and LV function in patients with EDFF<sup>26,36</sup></li> </ul>
Pulmonary regurgitation	<ul> <li>EDFF is typically associated with the transannular patch but is not usually present in patients in whom the pulmonary valve had been preserved during primary repair<sup>8</sup></li> </ul>
Residual obstruction	<ul> <li>Some degree of residual RVOT obstruction after ToF repair may be beneficial by protecting the RV from enlarging even in the presence of large PR<sup>38,41</sup></li> </ul>
Pulmonary arterial bed capacitance and respiration	<ul> <li>The respiratory cycle acts as an additional hemodynamic pump, which becomes more important when effective pulmonary flow attributable to RV contraction decreases and acts as a "suction" mechanism predisposing to EDFF<sup>33</sup></li> <li>EDFF increases during normal inspiration and during the expiratory phase of positive pressure ventilation, probably because of increased systemic venous return<sup>5</sup></li> <li>EDFF is less common among patients with pulmonary attresia, despite their predilection to RV noncompliance, as they have stiff, diminutive pulmonary arteries with poor arborization.<sup>37</sup> Similarly, EDFF may be attenuated by aging. Conversely, increased pulmonary artery capacitance may contribute to EDFF</li> </ul>

ACE indicates angiotensin-converting enzyme; EDFF, end-diastolic forward flow; LA, left atrial; LV, left ventricular; PR, pulmonary regurgitation; RA, right atrial; RV, right ventricular; RVEDVi, RV end-diastolic volume indexed; RVOT, RV outflow tract; and ToF, tetralogy of Fallot.

may attenuate EDFF. Conversely, increased pulmonary arterial bed capacitance decreases the resistance to pulmonary artery filling and might thereby increase or induce EDFF, even when RV compliance and filling pressures are normal. As shown in our meta-analysis, the severity of PR and the use of the transannular patch during primary repair of ToF are both significantly associated with EDFF, possibly because of lower pulmonary diastolic pressure. With pressure gradients of only 1 to 2 mm Hg governing EDFF, it is highly susceptible to small changes in preload, pulmonary artery bed capacitance, and PR.

More important, this meta-analysis found no significant associations of EDFF with typical markers of restrictive filling of the RV, including decreased tricuspid E-wave deceleration, decreased early diastolic tricuspid annular velocity, increased E/A ratio, increased E/E' (ratio between early ventricular filling velocity (E) and annulus velocity during early filling (E')), or RA enlargement, based on random-effects models (main analysis)

and only limited effects based on fixed-effects models (sensitivity analysis). This is in accordance with findings by DiLorenzo et al,63 who found that invasive evaluation of diastolic function with catheter-based RV enddiastolic pressure did not correlate with EDFF or any other echocardiographic parameters of diastolic function in patients with ToF. Similarly, Mori et al<sup>16</sup> reported that EDFF was inconsistently associated with RVRP, noting its presence in some patients with low pulmonary diastolic pressure (attributable to severe PR) and normal RA pressure. In fact, our meta-analysis revealed a lower early (E) inflow velocity through the tricuspid valve in patients with EDFF, in contrast to increased E in the conventional restrictive pattern. This finding could well be a manifestation of the Bernoulli principle, where transtricuspid velocities drop secondary to widening of the tricuspid annulus. However, Sjöberg et al<sup>55</sup> suggested that these decreased velocities might contribute to the lower diastolic kinetic energy observed on 4-dimensional flow CMR in patients with EDFF. As

Table 4	Unifying Theory	About Physiologica	and Clinical	Correlates of FDFF
		About i monologiou		

Phenotype 1: early-onset, "primary" EDFF	Phenotype 2: late-onset, "secondary" EDFF
Physiological correlates	
Small RVs with abnormal diastolic filling following directly after primary repair of ToF and probably related to fibrosis, myocardial injury, and other perioperative factors	Dilated RVs at late follow-up after primary repair of ToF, or may occur as a late stage of phenotype 1
Preventing further progression of PR and limiting the extent of volume overload	Pronounced volume overload attributable to longstanding PR, whereby filling of the RV becomes limited and RV pressure becomes larger than pulmonary artery pressure
Usually disappears days to months after the primary repair, but may be maintained into midterm follow-up in a subset of patients	Usually is maintained during long-term follow-up but may disappear after PVR
Associated with repair at older age as seen in the initial era of development of ToF repair	Associated with repair at younger age as seen in more contemporary management
Corresponds closest to actual RVRP	Only a subset of patients might have actual RVRP
Clinical correlates	
Longer ICU length of stay attributable to increased central venous pressure and low cardiac output state	Independent predictor of rapid RV enlargement
Improved exercise tolerance (higher peak VO <sub>2</sub> ) because of improved oxygenation, as EDFF contributes to forward flow and shortens duration of PR	Related to functional deterioration and worse exercise tolerance
Lower risk of arrhythmias and sudden death	Associated with increased risk of adverse outcomes, such as ventricular dysfunction and arrhythmias; persistent EDFF after PVR indicates worse prognosis

EDFF indicates end-diastolic forward flow; ICU, intensive care unit; PR, pulmonary regurgitation; PVR, pulmonary valve replacement; RV, right ventricular; RVRP, RV restrictive physiology; ToF, tetralogy of Fallot; and VO<sub>2</sub>, oxygen consumption.

kinetic energy reflects ventricular performance, it might be a potential early marker of ventricular dysfunction. In summary, clinicians are encouraged to look beyond EDFF to determine if their patients have RV diastolic dysfunction.

# A Unifying Theory About the Physiological and Clinical Correlates of EDFF

To reconcile the conflicting results in the literature, the observation of Lee et al,39 revealing that EDFF most commonly occurs at the ends of the RVEDVi spectrum (at  $\leq$ 115 and  $\geq$ 200 mL/m<sup>2</sup>), is key. Consider that there may be 2 main phenotypes of ToF in which EDFF is observed (Table 4). Representative pressurevolume curves for each of these phenotypes are presented in Figure 3. The first, which we refer to as early-onset, "primary" EDFF, matches the original cohorts described by Cullen et al<sup>5</sup> and Gatzoulis et al.<sup>6</sup> This phenotype more closely resembles a "true" RVRP, and occurs in association with small RVs with abnormal diastolic filling.<sup>34</sup> EDFF in these patients has its onset in the period around primary ToF repair. Cardiopulmonary bypass, myocardial edema, ventriculotomy, endomyocardial fibrosis, and the insertion of nonfunctional patches in the ventricular septum and across the right ventricular outflow tract might all be expected to impair RV diastolic performance.<sup>8</sup> Although increased central venous pressure and low cardiac output lead to longer intensive care unit length of stay in these patients, RVRP is eventually beneficial as it prevents further progression of PR, thereby improving exercise tolerance and reducing the risk of adverse outcomes.<sup>6–8</sup> Early-onset EDFF usually disappears days to months after the primary repair, although it may be maintained into midterm follow-up in a subset of patients.<sup>5,7</sup>

The first phenotype was more commonly observed in earlier ToF cohorts, when patients were operated at a later age and perioperative ventricular dysfunction was common.<sup>44</sup> Improvements in surgical techniques and myocardial preservation have led to improved diastolic function in the early and midterm period after repair, but might also have promoted a higher prevalence of a second phenotype.<sup>44</sup> Late-onset, "secondary" EDFF is a consequence of an overdistended ventricle and rightward shift of the pressure-volume curve.<sup>16,39</sup> The lack of RVRP in early follow-up allows for continuing RV remodeling and enlargement in the presence of longstanding PR. The severely dilated RV eventually becomes stiff or encounters space constraints attributable to the pericardium and the capacity of the thoracic cavity. In this setting, EDFF occurs without restricted RV filling or decreased RV volume.<sup>12</sup> This dilatation-related phenotype has been linked to severe PR,<sup>16</sup> fibrosis,<sup>45</sup> accelerated RV enlargement,<sup>54</sup> and increased risk of adverse outcomes.<sup>56</sup> Corroborating these observations, Lee et al<sup>39</sup> demonstrated that EDFF was associated with improved exercise tolerance (peak oxygen consumption) in patients with RVEDVi <170 mL/m<sup>2</sup>, but not in those with RVEDVi  $\geq$ 170 mL/m<sup>2</sup>.



**Figure 3.** Representative pressure-volume curves for the different phenotypes of end-diastolic forward flow (EDFF). The pressure-volume curve of the normal right ventricle (RV), which is characterized by its trapezoidal shape, is depicted in the middle (black contours). The early-onset, "primary" type of EDFF is associated with a small, restrictive RV (red shape on the left) with decreased myocardial compliance (end-diastolic pressure-volume relationship [EDPVR] 2 is shifted upward compared with EDPVR 1). In contrast, the late-onset, "secondary" type of EDFF presents as a dilated RV with a rightward shift of the pressure-volume relationship, either without (green shape on the right at EDPVR 1) or with marked myocardial stiffening (yellow shape on the right at EDPVR 2). ESPVR indicates end-systolic pressure-volume relationship.

# Perspectives for Future Research and Clinical Practice

EDFF was invariably treated as a binary feature in all studies. However, it is possible that characteristics, such as EDFF duration, mean and peak velocity, velocity time integral, and percentage of contribution to the stroke volume, may have their own implications. Although a few studies have reported such characteristics,<sup>8,30,34,37,45,48,57</sup> it will be a task for future investigations to determine how they correlate with patient characteristics, cardiac morphology and function, and outcomes. Having said that, it is clear that EDFF is an imperfect surrogate for poor RV compliance, so future studies should aim to identify more reliable markers for RVRP. Multiple parameters may be required, including tricuspid inflow characteristics, tricuspid valve annulus, hepatic veins, right atrial size, and collapsibility of the interior vena cava.<sup>64</sup> In addition, more investigations using invasive measurements of filling pressures are warranted to validate findings from noninvasive modalities. Of interest, recent advances have made it possible to measure RV pressure-volume loops more routinely in clinical and research settings, as described in an outstanding recent review by Brener et al.65

More research is required to further elucidate how EDFF and different hemodynamics relate to prognosis and anticipated clinical needs. Machine learning techniques could be harnessed to identify phenotypical clusters among patients with EDFF. In addition, the relevance of EDFF for risk stratification for common procedures in rToF, such as placement of implantable cardioverter-defibrillator and pulmonary valve replacement, should be investigated.<sup>66,67</sup> As an example of the latter, Tominaga et al<sup>56</sup> showed that EDFF may disappear after pulmonary valve replacement but signals worse prognosis when it persists. It might be important to interpret this in conjunction with RV size, as patients with smaller RVs (<170 mL/ m<sup>2</sup>) have not consistently shown an effect of persistent EDFF on the risk of arrhythmias.<sup>68</sup> Current surgical practices with more valve-sparing operations and fewer transannular patches for ToF are likely already influencing the context in which EDFF is observed, so research into the implications of EDFF may differ from the historical baselines established in this analysis.69

#### Limitations and Sources of Heterogeneity

Our meta-analysis was limited to univariate analyses. Residual confounding by year of publication or enrollment, age at initial repair, timing of assessment or pulmonary valve replacement relative to initial repair, as well as anatomical and functional characteristics cannot be excluded. More important, patients from older cohorts underwent initial repair with different techniques and perioperative management compared with contemporary practice. Although subgroup analyses of all investigated factors comparing studies with large RVEDVi versus those with low RVEDVi might have corroborated our framework including the 2 phenotypes, these data were not consistently reported in a sufficient number of studies to perform such analyses. Meta-regression analyses were conducted instead, but these were likewise limited by modest power. Similarly, subgroup analyses based on the timing of initial repair and subsequent interventions could further enhance our understanding of EDFF and may be the subject of future clinical investigations. Furthermore, it should be considered that our analyses were not corrected for multiple testing given the exploratory nature of our study, such that our estimates might need to be validated in future studies. Finally, the technical limitations of echocardiography and CMR to identify EDFF might have affected our findings. In this regard, 2 of the studies that primarily defined EDFF based on CMR ascertained their results based on Doppler echocardiography. Sani et al<sup>52</sup> found a comparable prevalence of EDFF with both echocardiography (56.7%) and CMR (60.0%; P=0.792). In contrast, Lee et al<sup>39</sup> found that CMR identified a higher prevalence of EDFF (64.4%) compared with Doppler echocardiography (44.4%; *P*=0.039), with only 58.6% of the CMR cases being confirmed on Doppler echocardiography. Furthermore, they found that Doppler-based EDFF correlated less well with peak oxygen consumption percentage (*r*=0.381; *P*=0.026) than did CMR-based EDFF (*r*=0.536; *P*=0.001). Kutty et al<sup>37</sup> found a modest correlation between both modalities (Fleiss'  $\kappa$ =0.597). The finding of our subgroup analysis that overall there was only a marginally higher EDFF prevalence with CMR compared with Doppler echocardiography (50.8% versus 45.7%; *P*=0.332) is reassuring, although future investigations directly comparing both modalities will likely advance our understanding.

#### CONCLUSIONS

In this meta-analysis, EDFF occurred in 46.5% of patients with rToF and is associated with the use of a transannular patch, longer intensive care unit length of stay, greater RV indexed volumes and mass, smaller E-wave velocity at the tricuspid valve, and greater PR. EDFF is not specific of RVRP and has multiple alternative causes. Our review supports a specific reconciliation of the conflicting EDFF literature, based on the presence of 2 main phenotypes: (1) early-onset, "primary" EDFF and (2) late-onset, "secondary" EDFF. The latter has become more prevalent in contemporary practice, with improved perioperative ventricular diastolic function but progressive dilatation resulting from longstanding PR. Future studies should refine the diagnostic criteria for RVRP and clarify the potential prognostic relevance of EDFF in various settings.

#### **ARTICLE INFORMATION**

Received September 18, 2021; accepted February 2, 2022.

#### Affiliations

Helen B. Taussig Heart Center, The Johns Hopkins Hospital and School of Medicine, Baltimore, MD (J.V.d., D.A.D., S.K.); Department of Cardiovascular Diseases, University Hospitals Leuven and Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium (J.V.d., A.S., W.B.); Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium (E.D.); Division of Cardiovascular Medicine, Radcliffe Department of Medicine, Oxford Cardiovascular Clinical Research Facility, University of Oxford, United Kingdom (A.S.); Division of Pediatric Cardiology, Augusta University, Augusta, GA (P.S.); and Congenital and Structural Cardiology, UZ Leuven, Leuven, Belgium (W.B.).

#### **Acknowledgments**

Author Contributions: Van den Eynde: concept/design, data collection, data interpretation, drafting article, critical revision of article, and approval of article; Derdeyn: concept/design, data collection, data interpretation, drafting article, critical revision of article, and approval of article, critical revision of article, and approval of article, critical revision of article, and approval of article; Budts: data interpretation, critical revision of article, and approval of article; Budts: data interpretation, critical revision of article, and approval of article; Budts: data interpretation, critical revision of article, and approval of article; Kutty: data interpretation, critical revision of article, and approval of article; Kutty: data interpretation, critical revision of article, and approval of article.

#### **Sources of Funding**

None.

#### Disclosures

Budts is proctor for Abbott and Occlutech. Kutty is consultant for GE Healthcare. Van den Eynde was supported by the Belgian American Educational Foundation. The remaining authors have no disclosures to report.

#### Supplemental Material

Data S1 Figures S1–S15

#### REFERENCES

- van der Linde D, Konings EEM, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJM, Roos-Hesselink JW. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. *J Am Coll Cardiol.* 2011;58:2241–2247. doi: 10.1016/j.jacc.2011.08.025
- 2. Apitz C, Webb GD, Redington AN. Tetralogy of Fallot. Lancet. 2009;374:1462–1471. doi: 10.1016/S0140-6736(09)60657-7
- Carvalho JS, Shinebourne EA, Busst C, Rigby ML, Redington AN. Exercise capacity after complete repair of tetralogy of Fallot: deleterious effects of residual pulmonary regurgitation. *Heart.* 1992;67:470–473. doi: 10.1136/hrt.67.6.470
- Dennis M, Moore B, Kotchetkova I, Pressley L, Cordina R, Celermajer DS. Adults with repaired tetralogy: low mortality but high morbidity up to middle age. *Open Heart*. 2017;4:e000564. doi: 10.1136/openh rt-2016-000564
- Cullen S, Shore D, Redington A. Characterization of right ventricular diastolic performance after complete repair of tetralogy of Fallot. *Circulation*. 1995;91:1782–1789. doi: 10.1161/01.CIR.91.6.1782
- Gatzoulis MA, Clark AL, Cullen S, Newman CGH, Redington AN. Right ventricular diastolic function 15 to 35 years after repair of tetralogy of Fallot: restrictive physiology predicts superior exercise performance. *Circulation*. 1995;91:1775–1781. doi: 10.1161/01.CIR.91.6.1775
- Norgård G, Gatzoulis MA, Josen M, Cullen S, Redington AN. Does restrictive right ventricular physiology in the early postoperative period predict subsequent right ventricular restriction after repair of tetralogy of Fallot? *Heart.* 1998;79:481–484. doi: 10.1136/hrt.79.5.481
- Eroglu AG, Sarioglu A, Sarioglu T. Right ventricular diastolic function after repair of tetralogy of Fallot: its relationship to the insertion of a "transannular" patch. *Cardiol Young*. 1999;9:384–391. doi: 10.1017/ S1047951100005187
- Gibbs JL, Wilson N, Witsenburg M, Williams GJ, Goldberg SJ. Diastolic forward blood flow in the pulmonary artery detected by doppler echocardiography. J Am Coll Cardiol. 1985;6:1322–1328. doi: 10.1016/ S0735-1097(85)80220-5
- Redington AN, Penny D, Rigby ML, Hayes A. Antegrade diastolic pulmonary arterial flow as a marker of right ventricular restriction after complete repair of pulmonary atresia with intact septum and critical pulmonary valvar stenosis. *Cardiol Young*. 1992;2:382–386. doi: 10.1017/ S1047951100007988
- Helbing WA, Niezen RA, Le Cessie S, van der Geest RJ, Ottenkamp J, de Roos A. Right ventricular diastolic function in children with pulmonary regurgitation after repair of tetralogy of Fallot: volumetric evaluation by magnetic resonance velocity mapping. *J Am Coll Cardiol*. 1996;28:1827–1835. doi: 10.1016/S0735-1097(96)00387-7
- Lu JC, Cotts TB, Agarwal PP, Attili AK, Dorfman AL. Relation of right ventricular dilation, age of repair, and restrictive right ventricular physiology with patient-reported quality of life in adolescents and adults with repaired tetralogy of fallot. *Am J Cardiol.* 2010;106:1798–1802. doi: 10.1016/j.amjcard.2010.08.021
- Samyn MM, Kwon EN, Gorentz JS, Yan K, Danduran MJ, Cava JR, Simpson PM, Frommelt PC, Tweddell JS. Restrictive versus nonrestrictive physiology following repair of tetralogy of Fallot: is there a difference? J Am Soc Echocardiogr. 2013;26:746–755. doi: 10.1016/j. echo.2013.03.019
- Van den Berg J, Wielopolski PA, Meijboom FJ, Witsenburg M, Bogers AJJC, Pattynama PMT, Helbing WA. Diastolic function in repaired tetralogy of fallot at rest and during stress: assessment with MR imaging. *Radiology*. 2007;243:212–219. doi: 10.1148/radiol.2431060213

- Ahmad N, Kantor PF, Grosse-Wortmann L, Seller N, Jaeggi ET, Friedberg MK, Mertens L. Influence of RV restrictive physiology on LV diastolic function in children after tetralogy of Fallot repair. J Am Soc Echocardiogr. 2012;25:866–873. doi: 10.1016/j. echo.2012.05.011
- Mori Y, Murakami T, Inoue N, Kaneko S, Nakashima Y, Koide M. Is the presence of end-diastolic forward flow specific for restrictive right ventricular physiology in repaired tetralogy of Fallot? *Int J Cardiol.* 2017;240:187–193. doi: 10.1016/j.ijcard.2017.04.021
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi: 10.1136/bmj.n71
- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. *J Am Med Assoc.* 2000;283:2008–2012. doi: 10.1001/jama.283.15.2008
- Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol.* 2005;5:13. doi: 10.1186/1471-2288-5-13
- Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327:557–560. doi: 10.1136/ bmj.327.7414.557
- DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. *Contemp Clin Trials*. 2007;28:105–114. doi: 10.1016/j.cct.2006.04.004
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics*. 1994;50:1088. doi: 10.2307/2533446
- Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315:629–634. doi: 10.1136/bmj.315.7109.629
- Aburawi EH, Munkhammar P, Carlsson M, El-Sadig M, Pesonen E. Coronary flow dynamics in children after repair of tetralogy of Fallot. *Int J Cardiol.* 2014;172:122–126. doi: 10.1016/j.ijcard.2013.12.188
- Apitz C, Latus H, Binder W, Uebing A, Seeger A, Bretschneider C, Sieverding L, Hofbeck M. Impact of restrictive physiology on intrinsic diastolic right ventricular function and lusitropy in children and adolescents after repair of tetralogy of Fallot. *Heart*. 2010;96:1837–1841. doi: 10.1136/hrt.2010.203190
- Babu-Narayan SV, Uebing A, Davlouros PA, Kemp M, Davidson S, Dimopoulos K, Bayne S, Pennell DJ, Gibson DG, Flather M, et al. Randomised trial of ramipril in repaired tetralogy of Fallot and pulmonary regurgitation: the APPROPRIATE study (Ace inhibitors for Potential PRevention of the deleterious effects of Pulmonary Regurgitation in Adults with repaired TEtralogy of Fallot). *Int J Cardiol*. 2012;154:299– 305. doi: 10.1016/j.ijcard.2010.09.057
- Bonello B, Kempny A, Uebing A, Li W, Kilner PJ, Diller G-P, Pennell DJ, Shore DF, Ernst S, Gatzoulis MA, et al. Right atrial area and right ventricular outflow tract akinetic length predict sustained tachyarrhythmia in repaired tetralogy of Fallot. *Int J Cardiol.* 2013;168:3280–3286. doi: 10.1016/j.ijcard.2013.04.048
- Cardoso SM, Miyague NI. Right ventricular diastolic dysfunction in the postoperative period of tetralogy of Fallot. Arq Bras Cardiol. 2003;80:194–197, 198–201. doi: 10.1590/s0066-782x2003000200008
- Chaturvedi RR, Shore DF, Lincoln C, Mumby S, Kemp M, Brierly J, Petros A, Gutteridge JMG, Hooper J, Redington AN. Association with myocardial injury and oxidative stress. *Circulation*. 1999;100:1540– 1547. doi: 10.1155/2020/5732956
- Cheng AL, Kaslow AM, Pruetz JD, Lu JC, Wood JC, Detterich JA. Differences in right ventricular physiologic response to chronic volume load in patients with repaired pulmonary atresia intact ventricular septum/critical pulmonary stenosis versus tetralogy of Fallot. *Pediatr Cardiol.* 2019;40:526–536. doi: 10.1007/s00246-018-2009-2
- Cheung MMH, Davis AM, Wilkinson JL, Weintraub RG. Evidence for restoration of genetic growth potential. *Congenit Heart Dis.* 2003;5500:1340–1343. doi: 10.1136/heart.89.11.1340
- Choi JY, Kwon HS, Yoo BW, Shin JII, Sul JH, Park HK, Park YH. Right ventricular restrictive physiology in repaired tetralogy of Fallot is associated with smaller respiratory variability. *Int J Cardiol.* 2008;125:28–35. doi: 10.1016/j.ijcard.2007.02.020
- Clark AL, Gatzoulis MA, Redington AN. Ventilatory responses to exercise in adults after repair of tetralogy of Fallot. *Br Heart J.* 1995;73:445–449. doi: 10.1136/hrt.73.5.445

- Gatzoulis MA, Norgård G, Redington AN. Biventricular long axis function after repair of tetralogy of Fallot. *Pediatr Cardiol.* 1998;19:128–132. doi: 10.1007/s002469900260
- Kordybach-Prokopiuk M, Dobrowolski P, Kowalski M, Hoffman P. Differences in regional diastolic function between restrictive and normal right ventricular physiology in adult patients late after tetralogy of Fallot repair. *Kardiol Pol.* 2018;76:1458–1464. doi: 10.5603/KP.a2018.0145
- Krupickova S, Li W, Cheang MH, Rigby ML, Uebing A, Davlouros P, Dimopoulos K, Di Salvo G, Fraisse A, Swan L, et al. Ramipril and left ventricular diastolic function in stable patients with pulmonary regurgitation after repair of tetralogy of Fallot. *Int J Cardiol.* 2018;272:64–69. doi: 10.1016/j.ijcard.2018.07.132
- Kutty S, Valente AM, White MT, Hickey K, Danford DA, Powell AJ, Geva T. Usefulness of pulmonary arterial end-diastolic forward flow late after tetralogy of Fallot repair to predict a "restrictive" right ventricle. *Am J Cardiol.* 2018;121:1380–1386. doi: 10.1016/j.amjcard.2018.02.025
- Latus H, Gummel K, Rupp S, Valeske K, Akintuerk H, Jux C, Bauer J, Schranz D, Apitz C. Beneficial effects of residual right ventricular outflow tract obstruction on right ventricular volume and function in patients after repair of tetralogy of Fallot. *Pediatr Cardiol.* 2013;34:424– 430. doi: 10.1007/s00246-012-0476-4
- Lee W, Yoo SJ, Roche SL, Kantor P, Van Arsdell G, Park EA, Redington A, Grosse-Wortmann L. Determinants and functional impact of restrictive physiology after repair of tetralogy of Fallot: new insights from magnetic resonance imaging. *Int J Cardiol.* 2013;167:1347–1353. doi: 10.1016/j.ijcard.2012.04.008
- Luijnenburg SE, Peters RE, van der Geest RJ, Moelker A, Roos-Hesselink JW, de Rijke YB, Mulder BJM, Vliegen HW, Helbing WA. Abnormal right atrial and right ventricular diastolic function relate to impaired clinical condition in patients operated for tetralogy of Fallot. *Int J Cardiol.* 2013;167:833–839. doi: 10.1016/j.ijcard.2012.02.011
- Maskatia SA, Spinner JA, Morris SA, Petit CJ, Krishnamurthy R, Nutting AC. Effect of branch pulmonary artery stenosis on right ventricular volume overload in patients with tetralogy of fallot after initial surgical repair. *Am J Cardiol.* 2013;111:1355–1360. doi: 10.1016/j.amjcard.2013.01.278
- Maskatia SA, Morris SA, Spinner JA, Krishnamurthy R, Altman CA. Echocardiographic parameters of right ventricular diastolic function in repaired tetralogy of Fallot are associated with important findings on magnetic resonance imaging. *Congenit Heart Dis.* 2015;10:E113–E122. doi: 10.1111/chd.12265
- Mercer-Rosa L, Fogel MA, Paridon SM, Rychik J, Yang W, Goldmuntz E. Revisiting the end-diastolic forward flow (restrictive physiology) in tetralogy of Fallot: an exercise, echocardiographic, and magnetic resonance study. *JACC Cardiovasc Imaging*. 2018;11:1547–1548.
- Munkhammar P, Cullen S, Jögi P, de Leval M, Elliott M, Norgård G. Early age at repair prevents restrictive right ventricular (RV) physiology after surgery for tetralogy of Fallot (TOF): diastolic RV function after TOF repair in infancy. J Am Coll Cardiol. 1998;32:1083–1087. doi: 10.1016/ S0735-1097(98)00351-9
- Munkhammar P, Carlsson M, Arheden H, Pesonen E. Restrictive right ventricular physiology after tetralogy of Fallot repair is associated with fibrosis of the right ventricular outflow tract visualized on cardiac magnetic resonance imaging. *Eur Heart J Cardiovasc Imaging*. 2013;14:978– 985. doi: 10.1093/ehjci/jet009
- Norgård G, Gatzoulis MA, Moraes F, Lincoln C, Shore DF, Shinebourne EA, Redington AN. Relationship between type of outflow tract repair and postoperative right ventricular diastolic physiology in tetralogy of Fallot. *Circulation*. 1996;94:3276–3280. doi: 10.1161/01.CIR.94.12.3276
- Peng EWK, Spooner R, Young D, Danton MHD. Acute B-type natriuretic peptide response and early postoperative right ventricular physiology following tetralogy of Fallot's repair. *Interact Cardiovasc Thorac Surg.* 2012;15:335–339. doi: 10.1093/icvts/ivs150
- Pijuan-Domenech A, Pineda V, Castro MA, Sureda-Barbosa C, Ribera A, Cruz LM, Ferreira-Gonzalez I, Dos-Subirà L, Subirana-Domènech T, Garcia-Dorado D, et al. "Pulmonary valve replacement diminishes the presence of restrictive physiology and reduces atrial volumes": a prospective study in tetralogy of Fallot patients. *Int J Cardiol.* 2014;177:261– 265. doi: 10.1016/j.ijcard.2014.09.009
- Rathore KS, Agrawal SK, Kapoor A. Restrictive physiology in tetralogy of Fallot: exercise and arrhythmogenesis. *Asian Cardiovasc Thorac Ann.* 2006;14:279–283. doi: 10.1177/021849230601400403
- Sachdev MS, Bhagyavathy A, Varghese R, Coelho R, Kumar RS. Right ventricular diastolic function after repair of tetralogy of fallot. *Pediatr Cardiol*. 2006;27:250–255. doi: 10.1007/s00246-005-1186-y

- Sandeep B, Huang X, Xu F, Su P, Wang T, Sun X. Etiology of right ventricular restrictive physiology early after repair of tetralogy of Fallot in pediatric patients. *J Cardiothorac Surg.* 2019;14:84. doi: 10.1186/s1301 9-019-0909-8
- Sani ZA, Samiei N, Khajali Z, Mirrazeghi F, Gholamipoor D, Rouzitalab M, Bayat M, Behjati M, Ghadrdoost B, Rahimi S. Assessment of right ventricular myocardial fibrosis and restrictive physiology in patients with repaired tetralogy of fallot: a comparison between cardiac magnetic resonance and transthoracic echocardiography. *Iran Heart J.* 2020;21:87–97.
- Shekerdemian LS, Bush A, Shore DF, Lincoln C, Redington AN. Cardiorespiratory responses to negative pressure ventilation after tetralogy of fallot repair: a hemodynamic tool for patients with a low-output state. J Am Coll Cardiol. 1999;33:549–555. doi: 10.1016/S0735-1097(98)00598-1
- Shin YR, Jung JW, Kim NK, Choi JY, Kim YJ, Shin HJ, Park YH, Park HK. Factors associated with progression of right ventricular enlargement and dysfunction after repair of tetralogy of Fallot based on serial cardiac magnetic resonance imaging. *Eur J Cardiothoracic Surg.* 2016;50:464–469. doi: 10.1093/ejcts/ezw049
- Sjöberg P, Bidhult S, Bock J, Heiberg E, Arheden H, Gustafsson R, Nozohoor S, Carlsson M. Disturbed left and right ventricular kinetic energy in patients with repaired tetralogy of Fallot: pathophysiological insights using 4D-flow MRI. *Eur Radiol.* 2018;28:4066–4076. doi: 10.1007/ s00330-018-5385-3
- Tominaga Y, Taira M, Kido T, Kanaya T, Araki K, Watanabe T, Sakaniwa R, Toda K, Kuratani T, Ueno T, et al. Persistent end-diastolic forward flow after pulmonary valve replacement in patients with repaired tetralogy of Fallot. *Eur J Cardiothorac Surg.* 2021;60:516–523. doi: 10.1093/ ejcts/ezab098
- Vukomanović V, Stajević M, Jovanović I, Kosutić J, Sehić I, Milovanović V. Echocardiographic analysis of the subtypes of right ventricular restrictive physiology in surgically treated patients with tetralogy of Fallot. *Cardiol Young.* 2006;16:549–555. doi: 10.1017/S104795110600120X
- Xu Z, Zhang M, Zhu L, Gong X, Li J. Elevated plasma B-type natriuretic peptide and C-reactive protein levels in children with restrictive right ventricular physiology following tetralogy of Fallot repair. *Congenit Heart Dis.* 2014;9:521–528. doi: 10.1111/chd.12166
- Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I. *Circulation*. 2008;117:1436–1448. doi: 10.1161/CIRCULATIONAHA.107.653576
- 60. Bastos MB, Burkhoff D, Maly J, Daemen J, den Uil CA, Ameloot K, Lenzen M, Mahfoud F, Zijlstra F, Schreuder JJ, et al. Invasive left ventricle

pressure–volume analysis: overview and practical clinical implications. *Eur Heart J.* 2020;41:1286–1297. doi: 10.1093/eurheartj/ehz552

- Redington AN, Rigby ML, Hayes A, Penny D. Right ventricular diastolic function in children. *Am J Cardiol.* 1991;67:329. doi: 10.1016/0002-9149(91)90591-8
- 62. Bove T, Vandekerckhove K, Bouchez S, Wouters P, Somers P, Van Nooten G. Role of myocardial hypertrophy on acute and chronic right ventricular performance in relation to chronic volume overload in a porcine model: relevance for the surgical management of tetralogy of Fallot. *J Thorac Cardiovasc Surg.* 2014;147:1956–1965. doi: 10.1016/j. jtcvs.2013.10.026
- DiLorenzo M, Hwang W-T, Goldmuntz E, Ky B, Mercer-Rosa L. Diastolic dysfunction in tetralogy of Fallot: comparison of echocardiography with catheterization. *Echocardiography*. 2018;35:1641–1648. doi: 10.1111/ echo.14113
- DiLorenzo MP, Bhatt SM, Mercer-Rosa L. How best to assess right ventricular function by echocardiography. *Cardiol Young*. 2015;25:1473. doi: 10.1017/S1047951115002255
- Brener MI, Masoumi A, Ng VG, Tello K, Bastos MB, Cornwell WK, Hsu S, Tedford RJ, Lurz P, Rommel K-P, et al. Invasive right ventricular pressure-volume analysis: basic principles, clinical applications, and practical recommendations. *Circ Heart Fail*. 2022;15:e009101. doi: 10.1161/CIRCHEARTFAILURE.121.009101
- Van den Eynde J, Sá MPBO, Vervoort D, Roever L, Meyns B, Budts W, Gewillig M, Ruhparwar A, Zhigalov K, Weymann A. Pulmonary valve replacement in tetralogy of Fallot: an updated meta-analysis. *Ann Thorac Surg.* 2020:S0003-4975(20)32173-1. doi: 10.1016/j.athor acsur.2020.11.040
- 67. Van den Eynde J, Callahan CP, Lo Rito M, Hussein N, Carvajal H, Guariento A, Ruhparwar A, Weymann A, Budts W, Gewillig M, et al. Tricuspid valve intervention at the time of pulmonary valve replacement in adults with congenital heart disease: a systematic review and meta-analysis. J Am Heart Assoc. 2021;10:22909. doi: 10.1161/ JAHA.121.022909
- Van den Eynde J, Derdeyn E, Danford D, Kutty S. Clinical trajectory and the interpretation of end-diastolic forward flow in tetralogy of Fallot. *Eur J Cardiothoracic Surg.* 2021;60:1241. doi: 10.1093/ EJCTS/EZAB283
- Blais S, Marelli A, Vanasse A, Dahdah N, Dancea A, Drolet C, Dallaire F. Comparison of long-term outcomes of valve-sparing and transannular patch procedures for correction of tetralogy of Fallot. *JAMA Netw Open*. 2021;4:e2118141. doi: 10.1001/jamanetworkopen.2021.18141

# SUPPLEMENTAL MATERIAL

Data S1.

#### **Supplemental Methods**

Search strategy.

<u>PubMed</u> (n=200 on March 8, 2021)

("Tetralogy of Fallot"[Mesh] OR fallot\* tetralogy OR tetralogy of fallot) AND (restrictive OR end-diastolic forward flow OR end diastolic forward flow OR antegrade diastolic pulmonary flow OR antegrade diastolic flow) in all fields

Embase (n=210 on March 8, 2021)

('fallot tetralogy'/exp OR 'fallot\* tetralogy' OR 'tetralogy of fallot') AND ('restrictive' OR 'enddiastolic forward flow' OR 'end diastolic forward flow' OR 'antegrade diastolic pulmonary flow' OR 'antegrade diastolic pulmonary artery flow' OR 'antegrade diastolic flow') in all fields

<u>Scopus</u> (n=142 on March 8, 2021)

(TITLE-ABS-KEY ("fallot's tetralogy" OR "fallot\* tetralogy" OR "tetralogy of fallot") AND TITLE-ABS-KEY ("restrictive" OR "end-diastolic forward flow" OR "end diastolic forward flow" OR "antegrade diastolic pulmonary flow" OR "antegrade diastolic pulmonary artery flow" OR "antegrade diastolic flow"))

#### **Supplemental Results**

#### Subgroup analyses

Subgroup analysis revealed that significantly different results were observed by prospective and retrospective studies for the following variables: right ventricular mass indexed (RVMi), right ventricular end-diastolic pressure (RVEDP), left ventricular stroke volume indexed (LVSVi), and left ventricular ejection fraction (LVEF). Prospective studies reported a significantly greater RVMi in end-diastolic forward flow (EDFF) (mean difference [MD] 3.81 g/m<sup>2</sup>, 95% 1.42-6.21, 6 studies), whereas a retrospective study<sup>37</sup> reported lower RVMi (MD -0.70 g/m<sup>2</sup>, 95% CI -1.21;-0.18, 1 study) (p<0.001). Furthermore, retrospective studies reported higher RVEDP in patients with EDFF (MD 1.78, 95% CI 0.93-2.63, 3 studies), as well as lower LVSVi (MD -2.03, 95% CI -2.48;-1.57, 1 study<sup>37</sup>) and higher LVEF (MD 0.95%, 95% 0.60-1.30, 6 studies). In contrast, prospective studies found no significant differences in either RVEDP (MD 0.00 mmHg, 95% CI -0.75-0.75, 1 study<sup>25</sup>), LVSVi (MD -0.25 ml/m<sup>2</sup>, 95% CI -1.13-0.63, 1 study<sup>27</sup>), or LVEF (MD -1.08%, 95% CI -2.37-0.21, 3 studies) (test for subgroup differences: all p<0.001). Lastly, the association between transannular patch repair and EDFF found by prospective studies (odds ratio [OR] 2.46, 95% 1.47-4.13, 14 studies) was greater than that found by retrospective studies (OR 1.38, 95% CI 0.51-3.73, 7 studies) (test for subgroup differences: p=0.001). No other significant interaction effects were observed.

#### Meta-regression analyses

Meta-regression analysis revealed that in more recent samples (higher mean year of enrollment) reported a larger MD for right ventricular end-diastolic volume indexed (RVEDVi) (regression coefficient 1.762, 95% CI 0.395-3.129, p=0.018, 10 studies) and aortic cross-clamp time (regression coefficient 0.844, 95% CI 0.138-1.550, p=0.029, 6 studies) in EDFF compared to no EDFF. Furthermore, larger MD for RVEDVi were associated with larger MD for right

ventricular stroke volume indexed (RVSVi) (regression coefficient 0.465, 95% CI 0.144-0.786, p=0.016, 6 studies) and pulmonary regurgitation fraction (regression coefficient 0.214, 95% CI 0.003-0.424, p=0.048, 8 studies). Lastly, it was found that older age at evaluation was associated with smaller MD for RVSVi (regression coefficient -1.142, 95% CI -1.610;-0.674, p=0.003, 6 studies) and greater MD for N-terminal pro-brain natriuretic peptide (NT-proBNP) (regression coefficient 15.324, 95% CI 0.797-29.850, p=0.047, 3 studies). No other significant associations were found.

**Figure S1. Forest plots.** CI, confidence interval; EDFF, end-diastolic forward flow; MD, mean difference; SD, standard deviation.

## A. Age at repair (years)

Study	Total	Mean	EDFF SD	Total	No Mean	EDFF SD		Mean	Differ	ence		MD	95	%-CI	Weight (fixed)	Weight (random)
Ahmad 2012	58	1.00	0.55	54	0.83	1.38			ŧ			0.17	[-0.23;	0.56]	1.3%	8.3%
Bonello 2013	38	7.50	1.50	110	4.62	1.08			-	-		2.88	[2.36;	3.39]	0.7%	7.5%
Choi 2008	15	1.12	0.30	28	2.63	1.35			+			-1.51	[-2.03;	-0.99]	0.7%	7.5%
Helbing 1996	13	1.42	0.67	6	1.58	0.83			+			-0.17	[-0.93;	0.59]	0.3%	6.0%
Kordybach-Prokopiuk 2018	16	12.60	10.50	67	11.70	12.60		-	-			0.90	[-5.06;	6.86]	0.0%	0.2%
Kutty 2018	122	0.90	0.29	277	1.32	0.58			. <b>1</b>			-0.41	[-0.50;	-0.33]	27.1%	9.6%
Lee 2013	33	1.50	0.96	17	1.10	0.67			+			0.40	[-0.06;	0.86]	0.9%	7.9%
Mercer-Rosa 2018	77	0.35	0.07	11	0.35	0.10						0.00	[-0.06;	0.06]	53.1%	9.7%
Munkhammar 1998	13	0.77	0.18	34	0.64	0.26			<b>e</b>			0.13	[0.00;	0.26]	11.5%	9.5%
Norgard 1996	36	11.02	6.82	56	11.85	7.10		-	-+			-0.82	[-3.73;	2.08]	0.0%	1.0%
Norgard 1998 (early restriction)	16	11.07	6.75	18	1.20	0.33				- 2		9.88	[ 6.56; 1	13.19]	0.0%	0.8%
Norgard 1998 (late restriction)	10	10.93	6.75	22	3.16	1.57					+	7.77	[ 3.53; 1	12.00]	0.0%	0.5%
Samyn 2013	12	1.31	0.53	17	1.51	0.67			-			-0.20	[-0.63;	0.24]	1.0%	8.0%
Tominaga 2021	23	3.88	0.89	23	3.00	0.50			+			0.88	[ 0.46;	1.30]	1.1%	8.2%
van den Berg 2007	24	1.00	0.50	12	0.90	0.50			+			0.10	[-0.25;	0.45]	1.6%	8.6%
Xu 2014	30	1.48	1.70	50	0.78	0.60			+-			0.70	[0.07;	1.33]	0.5%	6.8%
Fixed-effects	536			802								-0.07	[-0.11;	0.02]	100.0%	
Random-effects									-			0.33	[-0.42;	1.08]		100.0%
Heterogeneity: $l^2 = 95\%$ , $p < 0.00$	1							1	1							
Test for overall effect (fixed effect)	: z = -2	.90 (p =	= 0.004	)			-10	-5	0	5	10					
Test for overall effect (random effe	ects): t	= 0.9	4(n = 0)	363)			10	0	-	~						

# B. Time of follow-up since repair (years)

		E	DFF		No E	DFF									Weight	Weight
Study	Total	Mean	SD	Total	Mean	SD		Mean	Diffe	rence	•	MD	95	5%-CI	(fixed)	(random)
Gatzoulis 1998	36	5.00	3.00	56	4.20	2.80				_		0.80	[-0.42;	2.02]	3.8%	13.6%
Helbing 1996	13	10.33	2.67	6	10.17	2.67		_	-			0.17	[-2.41;	2.75]	0.8%	6.8%
Kordybach-Prokopiuk 2018	16	20.90	6.10	67	21.80	7.10			•   -	-		-0.90	[-4.34;	2.54]	0.5%	4.5%
Kutty 2018	122	17.36	2.38	277	18.82	2.22		-				-1.46	[-1.96;	-0.96]	22.8%	17.9%
Mori 2017	23	13.40	8.86	39	12.38	9.44			1			- 1.02	[-3.66;	5.70]	0.3%	2.8%
Norgard 1998 (early restriction)	16	1.88	0.45	18	1.80	0.47						0.07	[-0.23;	0.38]	59.2%	18.6%
Norgard 1998 (late restriction)	10	2.00	1.00	22	1.70	1.10			+			0.30	[-0.47;	1.07]	9.4%	16.4%
Samyn 2013	12	14.25	3.00	17	13.00	3.00			-#-	•	-	1.25	[-0.97;	3.47]	1.1%	8.2%
van den Berg 2007	24	16.00	2.00	12	13.25	2.50				-•		2.75	[1.12;	4.38]	2.1%	11.1%
Fixed-effects	272			514					-			-0.16	[-0.39;	0.08]	100.0%	
Random-effects							-	-	-	- 1 - C		0.32	[-0.65;	1.29]		100.0%
Heterogeneity: $I^2 = 83\%$ , $p < 0.00$	1						1		1		1					
Test for overall effect (fixed effect	z = -1	1.30 (p =	= 0.19	4)			-4	-2	0	2	4					
Test for overall effect (random eff	ects): t	s = 0.75	(p =	0.472)												

## C. Age at study (years)

			EDFF		No	EDFF				Weight	Weight
Study	Total	Mean	SD	Total	Mean	SD	Mean Difference	MD	95%-CI	(fixed)	(random)
Aburawi 2014	9	11.00	2.60	11	10.00	0.90		1.00	[-0.78; 2.78]	2.5%	4.7%
Ahmad 2012	58	13.60	3.20	54	12.30	3.10		1.30	[ 0.13; 2.47]	5.9%	5.1%
Bonello 2013	38	36.77	3.14	110	30.02	3.25		6.75	[ 5.58; 7.92]	5.9%	5.1%
Chaturvedi 1999	4	1.88	1.60	7	1.31	0.45	-	0.57	[-1.03; 2.17]	3.1%	4.8%
Choi 2008	15	5.44	2.15	28	4.48	1.04	+	0.96	[-0.19; 2.11]	6.0%	5.1%
Cullen 1995	17	1.96	2.42	18	1.80	1.77	-	0.16	[-1.25; 1.57]	4.0%	5.0%
Gatzoulis 1995	17	28.30	6.60	12	27.60	5.50		0.70	[-3.72; 5.12]	0.4%	2.7%
Gatzoulis 1998	36	15.03	7.12	56	14.43	7.22		0.60	[-2.40; 3.60]	0.9%	3.7%
Helbing 1996	13	11.83	2.83	6	11.50	2.92		0.33	[-2.47; 3.13]	1.0%	3.9%
Kordybach-Prokopiuk 2018	16	30.30	9.90	67	31.80	12.00		-1.50	[-7.14; 4.14]	0.3%	2.1%
Kutty 2018	122	18.92	2.75	277	21.32	2.65	<b></b>	-2.40	[-2.98; -1.82]	23.9%	5.4%
Lee 2013	33	12.90	2.90	17	13.40	2.60		-0.50	[-2.08; 1.08]	3.2%	4.9%
Mercer-Rosa 2018	77	12.90	3.20	11	11.10	2.90		1.80	[-0.06; 3.66]	2.3%	4.7%
Mori 2017	23	15.83	9.64	39	15.63	11.73		0.20	[-5.19; 5.59]	0.3%	2.2%
Munkhammar 1998	13	5.90	3.60	34	3.40	2.70		2.50	[ 0.34; 4.66]	1.7%	4.4%
Rathore 2006	52	7.60	2.40	28	8.10	3.50		-0.50	[-1.95; 0.95]	3.8%	4.9%
Sachdev 2006	24	4.40	2.30	26	5.50	3.10		-1.10	[-2.61; 0.41]	3.5%	4.9%
Samyn 2013	12	16.25	4.00	17	15.00	2.67		1.25	[-1.34; 3.84]	1.2%	4.1%
Sandeep 2019	28	2.56	2.38	22	1.67	0.89	-	0.89	[-0.07; 1.85]	8.8%	5.2%
Sani 2020	18	25.40	9.10	12	28.20	9.80		-2.80	[-9.76; 4.16]	0.2%	1.6%
Shekerdemian 1999	8	3.25	3.92	15	2.05	1.62		1.20	[-1.64; 4.04]	1.0%	3.9%
Tominaga 2021	23	35.00	10.00	23	38.80	14.30		-3.80	[-10.93; 3.33]	0.2%	1.5%
van den Berg 2007	24	17.25	2.17	12	14.00	2.67		3.25	[ 1.51; 4.99]	2.6%	4.7%
Xu 2014	30	1.48	1.71	15	0.78	0.60		0.70	[ 0.02; 1.38]	17.2%	5.4%
Fixed-effects	710			917			8	0.33	[ 0.04; 0.61]	100.0%	
Random-effects								0.77	[-0.08; 1.62]		100.0%
Heterogeneity: $I^2 = 90\%$ , $p < 0$	0.001						I I I I I				

Heterogeneity:  $\Gamma = 90\%$ , p < 0.001Test for overall effect (fixed effect): z = 2.26 (p = 0.024) Test for overall effect (random effects):  $t_{23} = 1.87$  (p = 0.074)

-10 -5 0 5 10

**Figure S2. Forest plots.** BT, Blalock-Taussig; CI, confidence interval; EDFF, end-diastolic forward flow; MD, mean difference; OR, odds ratio; RVPA, right ventricle-pulmonary artery; SD, standard deviation.

#### A. Previous RVPA shunt



#### **B.** Previous BT shunt

		EDFF	Nol	EDFF				Weight	Weight
Study	Events	Total	Events	Total	Odds Ratio	OR	95%-CI	(fixed)	(random)
Cullen 1995	1	17	1	18		1.06	[0.06; 18.45]	2.6%	2.9%
Helbing 1996	4	13	1	6		- 2.22	[0.19; 25.72]	2.7%	4.0%
Gatzoulis 1995	2	20	2	18		0.89	[0.11; 7.06]	5.3%	5.6%
Munkhammar 1998	4	13	9	23	<b>_</b>	0.69	[0.16; 2.93]	12.6%	11.5%
Norgard 1996	14	36	30	56		0.55	[0.24; 1.29]	40.3%	33.1%
Norgard 1998 (early restriction)	6	16	6	18		1.20	[0.29; 4.91]	9.9%	12.1%
Rathore 2006	2	52	1	28	<b> </b>	1.08	[0.09; 12.46]	3.5%	4.0%
Samyn 2013	6	12	6	17		1.83	[0.41; 8.27]	7.0%	10.6%
Shekerdemian 1999	1	8	3	15		0.57	[0.05; 6.61]	5.1%	4.0%
Tominaga 2021	5	23	5	23		1.00	[0.25; 4.06]	11.0%	12.2%
Fixed-effects		210		222		0.87	[0.54; 1.40]	100.0%	
Random-effects					4	0.86	[0.62; 1.20]		100.0%
Heterogeneity: $I^2 = 0\%$ , $p = 0.960$									
Test for overall effect (fixed effect)	): z = -0.5	8 (p = (	0.562)		0.1 0.5 1 2 10				
Test for overall effect (random effect	ects): t <sub>9</sub> =	-0.99 (	p = 0.347	)					

## C. Aortic cross-clamp time (min)

Study	Total	Mean	EDFF SD	Total	No Mean	EDFF SD	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)
Cullen 1995	17	66.00	30.00	18	58.00	13.80		8.00	[-7.62; 23.62]	3.5%	10.0%
Helbing 1996	13	58.00	16.00	6	54.00	15.00		4.00	[-10.82; 18.82]	3.9%	10.6%
Norgard 1996	36	53.50	19.70	56	57.20	20.60		-3.70	[-12.10; 4.70]	12.0%	15.4%
Rathore 2006	52	70.50	12.10	28	66.20	7.70		4.30	[-0.05; 8.65]	44.7%	18.3%
Sachdev 2006	24	69.23	18.96	26	63.36	17.23		5.87	[-4.20; 15.94]	8.3%	14.1%
Sandeep 2019	28	102.89	17.14	22	76.40	13.74		- 26.49	[17.93; 35.05]	11.5%	15.3%
Xu 2014	30	51.00	19.00	50	42.00	9.00		9.00	[ 1.76; 16.24]	16.1%	16.3%
Fixed-effects	200			206			-	6.91	[ 4.00; 9.82]	100.0%	
Random-effects	79% p	< 0.001						7.79	[-1.05; 16.62]		100.0%
Test for overall effe	ct (fixed	d effect)	7 = 46	6(p < 1)	0 001)		-30 -20 -10 0 10 20 30				
Test for overall effe	ct (rand	lom effe	cts); t.	= 2.16	(p = 0.0)	75)	00 20 10 0 10 20 00				

**Figure S3. Forest plots.** CI, confidence interval; CPB, cardiopulmonary bypass; EDFF, enddiastolic forward flow; MD, mean difference; OR, odds ratio; SD, standard deviation.

### A. CPB time (min)

Study	Total	Mean	EDFF SD	Total	No Mean	EDFF SD	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)
Chaturvedi 1999	4	77.20	18.40	7	110.00	39.70		-32.80	[-67.30; 1.70]	1.9%	8.9%
Cullen 1995	17	104.00	32.00	18	92.00	19.80		12.00	[-5.75; 29.75]	7.2%	13.8%
Norgard 1996	36	82.30	33.00	56	90.90	8.20		-8.60	[-19.59; 2.39]	18.8%	15.8%
Rathore 2006	52	105.60	17.20	28	112.40	23.20		-6.80	[-16.58; 2.98]	23.7%	16.1%
Sachdev 2006	24	124.38	34.24	26	112.89	27.31		11.49	[-5.77; 28.75]	7.6%	14.0%
Sandeep 2019	28	131.00	20.70	22	100.20	12.10		30.80	[21.62; 39.98]	26.9%	16.2%
Xu 2014	30	90.00	33.00	50	70.00	18.00		20.00	[ 7.18; 32.82]	13.8%	15.3%
Fixed-effects Random-effects	191			207				8.94 5.96	[ 4.17; 13.71] [-12.24; 24.17]	100.0%	
Heterogeneity: $l^2$ = Test for overall effective Test for overall effective	88%, p ect (fixe ect (rand	d effect): dom effe	z = 3.6 cts): t <sub>e</sub> :	8 (p < 0 = 0.80 (	0.001) (p = 0.45	4)	-60 -40 -20 0 20 40 60		-		

#### **B.** Transatrial repair

Study	Events	EDFF Total	No Events	EDFF Total	Odds Ratio	OR	95%-CI	Weight (fixed)	Weight (random)
Aburawi 2014	9	9	11	11				0.0%	0.0%
Choi 2008	0	15	7	28		0.09	[0.00; 1.74]	31.5%	10.6%
Cullen 1995	2	17	1	18		2.27	[0.19; 27.58]	5.2%	14.6%
Munkhammar 1998	3	13	16	34		0.34	[0.08; 1.45]	41.5%	42.0%
Gatzoulis 1995	3	20	4	18		0.62	[0.12; 3.23]	21.8%	32.7%
Fixed-effects		74		109	-	0.42	[0.18; 1.02]	100.0%	
<b>Random-effects</b> Heterogeneity: $I^2 = 2^{10}$ Test for overall effect	%, $p = 0.3$	383 ect): z =	= -1.93 (p	= 0.054	0.1 1 10 100	0.47	[0.10; 2.23]		100.0%

Test for overall effect (random effects):  $t_3 = -1.53$  (p = 0.223)

## C. Transannular patch repair

		EDFF	No	EDFF				Weight	Weight
Study	Events	Total	Events	Total	Odds Ratio	OR	95%-CI	(fixed)	(random)
Aburawi 2014	5	9	2	11	+∺ •	5.62	[0.75; 42.36]	0.7%	3.0%
Ahmad 2012	36	58	26	54	+ <del>*</del> -	1.76	[0.83; 3.74]	8.7%	7.7%
Bonello 2013	23	38	62	110		1.19	[0.56; 2.52]	10.7%	7.7%
Chaturvedi 1999	1	4	2	7		0.83	[0.05; 13.63]	0.9%	1.8%
Choi 2008	13	15	9	28	· · · · · · · · · · · · · · · · · · ·	13.72	[2.54; 74.13]	0.7%	3.8%
Cullen 1995	8	17	5	18		2.31	[0.57; 9.41]	2.2%	4.8%
Gatzoulis 1995	1	20	0	18		2.85	[0.11; 74.38]	0.4%	1.4%
Helbing 1996	9	13	1	6	•	11.25	[0.97; 130.22]	0.4%	2.3%
Kordybach-Prokopiuk 2018	6	16	27	67		0.89	[0.29; 2.73]	5.6%	5.9%
Kutty 2018	75	122	147	227		0.87	[0.55; 1.37]	33.8%	9.2%
Lee 2013	25	33	12	17		1.30	[0.35; 4.84]	3.3%	5.1%
Mercer-Rosa 2018	77	77	11	11				0.0%	0.0%
Norgard 1996	20	36	40	56		0.50	[0.21; 1.20]	11.9%	7.1%
Norgard 1998 (early restriction)	14	16	8	18	· · · · · · · · · · · · · · · · · · ·	8.75	[1.52; 50.31]	0.8%	3.7%
Rathore 2006	36	52	19	28	<b>+</b> !}-	1.07	[0.40; 2.86]	6.5%	6.5%
Sachdev 2006	14	24	5	26		5.88	[1.65; 20.91]	1.7%	5.3%
Sandeep 2019	22	28	6	22		9.78	[2.66; 35.95]	1.2%	5.1%
Samyn 2013	4	12	4	17		1.62	[0.31; 8.39]	1.9%	4.0%
Shekerdemian 1999	4	8	4	15		2.75	[0.46; 16.59]	1.2%	3.5%
Tominaga 2021	8	23	9	23		0.83	[0.25; 2.75]	5.0%	5.6%
van den Berg 2007	17	24	6	12		2.43	[0.58; 10.18]	2.0%	4.7%
Xu 2014	30	30	42	50		- 12.20	[0.68; 219.48]	0.4%	1.7%
Fixed-effects		675		841	•	1.54	[1.22; 1.94]	100.0%	
Random-effects					÷	1.98	[1.26; 3.11]		100.0%
Heterogeneity: $I^2 = 56\%, p < 0.00$	1						-		

Test for overall effect (fixed effect): z = 3.67 (p < 0.001) Test for overall effect (random effects):  $t_{20} = 3.17$  (p = 0.005)

0.01 0.1 1 10 100

**Figure S4. Forest plots.** CI, confidence interval; EDFF, end-diastolic forward flow; ICU, intensive care unit; MD, mean difference; OR, odds ratio; SD, standard deviation.

## A. Outflow patch repair

Study	Events	EDFF Total	No E Events	DFF Total	Odds Ratio	OR	95%-CI	Weight (fixed)	Weight (random)
Choi 2008 Cullen 1995 Gatzoulis 1995 Norgard 1998 (early restriction)	2 2 3 2	15 17 20 16	12 3 4 9	28 18 18 18		0.21 0.67 0.62 0.14	[0.04; 1.09] [0.10; 4.58] [0.12; 3.23] [0.02; 0.82]	34.9% 12.4% 17.2% 35.6%	27.2% 20.4% 27.6% 24.8%
<b>Fixed-effects</b> <b>Random-effects</b> Heterogeneity: $I^2 = 0\%$ , $p = 0.520$ Test for overall effect (fixed effect) Test for overall effect (random effect)	): z = -2.7; ects): t <sub>3</sub> =	68 2 (p = 0 -2.94 (	0.006) (p = 0.061)	82	0.1 0.5 1 2 10	0.31 0.32	[0.13; 0.72] [0.09; 1.10]	100.0% 	 100.0%

## **B. ICU Length of stay (days)**

Study	Total	E Mean	SD	Total	No E Mean	SD	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)
Chaturvedi 1999 Sachdev 2006 Sandeep 2019 Xu 2014	4 24 28 30	10.70 5.10 8.92 7.00	3.10 3.70 1.24 3.00	7 26 22 50	3.00 2.80 4.15 3.00	0.63 2.00 1.18 2.00		7.70 2.30 4.77 4.00	[4.63; 10.77] [0.63; 3.97] [4.10; 5.44] [2.79; 5.21]	3.2% 10.7% 65.7% 20.4%	13.2% 24.1% 33.9% 28.8%
<b>Fixed-effects</b> <b>Random-effects</b> Heterogeneity: $I^2 =$ Test for overall effe Test for overall effe	86 75%, p ect (fixe	e = 0.00 d effect) dom effe	7 ): z = 1 ects):	<b>105</b> 15.94 (µ t <sub>3</sub> = 4.6	o < 0.00 7 (p = 0	)1) 0.019)	-10 -5 0 5 10	1.44 1.34	[3.89; 4.99] [1.38; 7.29]	100.0%	100.0%

Figure S5. Forest plots. CI, confidence interval; EDFF, end-diastolic forward flow; MD, mean difference; RVEDVi, right ventricular end-diastolic volume indexed; RVESVi, right ventricular end-systolic volume indexed; RVSVi, right ventricular stroke volume indexed; SD, standard deviation.

## A. RVEDVi (mL/m<sup>2</sup>)

Study	Total	Mean	EDFF SD	Total	No Mean	EDFF SD	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)
Aburawi 2014	9	158.00	40.00	11	99.00	22.00	:i	- 59.00	[29.81; 88.19]	0.3%	4.0%
Apitz 2010	8	128.00	13.10	17	134.00	6.70		-6.00	[-15.62; 3.62]	2.4%	8.8%
Bonello 2013	38	125.50	6.50	110	126.00	8.30		-0.50	[-3.08; 2.08]	33.9%	10.2%
Eroglu 1999	25	62.62	29.62	19	81.12	26.75		-18.50	[-35.22; -1.78]	0.8%	6.8%
Helbing 1996	13	129.00	40.00	6	106.00	19.00	++ <del>++++++</del>	23.00	[-3.53; 49.53]	0.3%	4.5%
Kordybach-Prokopiuk 2018	16	158.80	45.10	67	143.20	40.10		15.60	[-8.49; 39.69]	0.4%	5.0%
Kutty 2018	122	142.30	10.90	277	131.20	7.60	<b>H</b>	11.10	[ 8.97; 13.23]	49.9%	10.2%
Lee 2013	33	167.50	41.00	17	166.20	59.10		1.30	[-30.08; 32.68]	0.2%	3.7%
Luijnenburg 2013	31	151.00	33.00	20	120.00	27.00		31.00	[14.42; 47.58]	0.8%	6.8%
Mercer-Rosa 2018	77	128.25	7.50	11	98.00	8.70	-	30.25	[24.84; 35.66]	7.7%	9.8%
Mori 2017	23	121.00	43.00	39	117.00	52.00		4.00	[-19.98; 27.98]	0.4%	5.0%
Munkhammar 2013	16	159.00	49.00	15	111.00	29.00		48.00	[19.86; 76.14]	0.3%	4.2%
Samyn 2013	12	126.00	14.00	17	109.80	19.50		16.20	[ 4.01; 28.39]	1.5%	8.1%
Sani 2020	18	191.50	61.30	12	154.40	37.60	+	37.10	[ 1.68; 72.52]	0.2%	3.1%
Tominaga 2021	23	165.17	31.30	23	156.00	44.00		9.17	[-12.89; 31.24]	0.5%	5.4%
van den Berg 2007	24	145.00	41.00	12	124.00	37.00		21.00	[-5.60; 47.60]	0.3%	4.5%
Fixed-effects	488			673			*	8.54	[ 7.03; 10.04]	100.0%	
Random-effects								14.71	[ 4.57; 24.84]		100.0%
Heterogeneity: $I^2 = 91\%$ , $p < 0$	0.001										
Test for overall effect (fixed ef	fect): z	= 11.12	(p < 0.0)	01)			-50 0 50				

Test for overall effect (fixed effect): z = 11.12 (p < 0.001)Test for overall effect (random effects):  $t_{15} = 3.09 (p = 0.007)$ 

# B. RVESVi (mL/m<sup>2</sup>)

			EDFF		No	EDFF
Study	Total	Mean	SD	Total	Mean	SD
Aburawi 2014	9	82.00	31.00	11	44.00	12.00
Bonello 2013	38	53.55	8.83	110	58.25	5.17
Kordybach-Prokopiuk 2018	16	88.00	27.80	67	77.90	27.90
Kutty 2018	122	68.90	6.27	227	67.35	5.65
Lee 2013	33	86.30	24.90	17	94.60	55.80
Luijnenburg 2013	31	79.00	22.00	20	63.00	19.00
Mercer-Rosa 2018	77	50.50	4.67	11	38.50	3.00
Munkhammar 2013	16	83.00	34.00	15	52.00	18.00
Sani 2020	18	120.80	50.00	12	99.20	31.90
Tominaga 2021	23	101.83	22.47	23	86.00	28.00
van den Berg 2007	24	150.25	25.50	12	71.25	26.83
Fixed-effects	407			525		
Random-effects						
Heterogeneity: $I^2 = 95\%$ , $p < 0$	0.001					
Test for overall effect (fixed eff	fect): z	= 7.76 (p	< 0.00	1)		
Test for overall effect (random	effects	s): $t_{10} = 2$	2.38 (p =	= 0.039	)	

Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)
; ;	38.00	[16.54; 59.46]	0.2%	6.2%
	-4.70	[-7.67; -1.73]	12.1%	14.0%
	10.10	[-5.07; 25.27]	0.5%	8.7%
	1.55	[ 0.22; 2.88]	59.9%	14.3%
	-8.30	[-36.15; 19.55]	0.1%	4.5%
i	16.00	[ 4.63; 27.37]	0.8%	10.5%
	12.00	[ 9.94; 14.06]	25.2%	14.2%
i +	31.00	[12.01; 49.99]	0.3%	7.1%
	21.60	[-7.71; 50.91]	0.1%	4.2%
	15.83	[ 1.16; 30.50]	0.5%	8.9%
	79.00	[60.71; 97.29]	0.3%	7.4%
	4.08	[ 3.05; 5.11]	100.0%	
	16.15	[ 1.01; 31.28]		100.0%
-50 0 50				

## C. RVSVi (mL/m<sup>2</sup>)

			EDFF		No	EDFF				Weight	Weight
Study	Total	Mean	SD	Total	Mean	SD	Mean Difference	MD	95%-CI	(fixed)	(random)
Bonello 2013	38	60.75	3.83	110	65.75	3.17		-5.00	[-6.35; -3.65]	36.4%	19.2%
Kutty 2018	122	72.75	5.17	227	63.45	3.93	-	9.30	[8.25; 10.35]	60.5%	19.2%
Luijnenburg 2013	31	72.00	14.00	20	57.00	12.00		15.00	[7.79; 22.21]	1.3%	17.0%
Mercer-Rosa 2018	77	77.00	16.00	11	61.00	17.00		16.00	[5.34; 26.66]	0.6%	14.8%
Munkhammar 2013	16	76.00	19.00	15	59.00	13.00		17.00	[5.60; 28.40]	0.5%	14.3%
van den Berg 2007	24	69.00	14.00	12	60.00	14.00		9.00	[-0.70; 18.70]	0.7%	15.4%
Fixed-effects	308			395				4.25	[ 3.43; 5.06]	100.0%	
Random-effects								9.57	[0.67; 18.47]		100.0%
Heterogeneity: $I^2 = 98$	3%, p <	< 0.001									
Test for overall effect	(fived	effect)	7 = 10.1	19 (n <	0.001)		20 10 0 10 20				

Test for overall effect (random effects):  $t_5 = 2.77$  (p = 0.040)

-20 -10 0 10 20

**Figure S6. Forest plots.** CI, confidence interval; EDFF, end-diastolic forward flow; MD, mean difference; RVEDP, right ventricular end-diastolic pressure; RVEF, right ventricular ejection fraction; RVESP, right ventricular end-systolic pressure; RVMi, right ventricular mass indexed; SD, standard deviation.

## A. RVMi (g/m²)

Study	Total	Mean	EDFF SD	Total	No Mean	EDFF SD		Mean	Differ	ence		MD	95	%-CI	Weight (fixed)	Weight (random)
Bonello 2013	38	55.00	20.00	110	51.00	14.00		-	-11-	ļ.		4.00	[-2.88: 1	0.881	0.3%	8.0%
Helbing 1996	13	26.00	6.00	5	25.00	7.00			i		-	1.00	[-5.95;	7.95	0.3%	7.9%
Kordybach-Prokopiuk 2018	16	33.70	10.00	67	28.70	8.70			- 11-	•••	_	5.00	[-0.32; 1	0.32	0.5%	10.8%
Kutty 2018	122	31.15	2.37	227	31.85	2.33						-0.70	[-1.22: -	0,181	54.3%	22.5%
Luijnenburg 2013	31	25.67	1.32	20	22.80	0.81						2.87	[ 2.29;	3.45	42.6%	22.5%
Samyn 2013	10	45.50	4.33	17	37.75	4.83				<u> </u>	•	7.75	[4.22; 1	1.28]	1.2%	15.3%
van den Berg 2007	24	25.00	7.00	12	23.00	6.00				<u> </u>		2.00	[-2.40;	6.40]	0.8%	13.0%
Fixed-effects	254			458					+			0.99	[0.61;	1.37]	100.0%	-
Random-effects										-		2.87	[ 0.14;	5.61]		100.0%
Heterogeneity: $I^2 = 94\%$ , $p < 1$	0.001							1	1		2					
Test for overall effect (fixed ef	fect): z	= 5.08	(p < 0.0)	01)			-10	-5	0	5	10					
Test for overall effect (random	effects	s): t <sub>e</sub> = :	2.57 (p	= 0.042	2)											

### B. RVEF (%)

			EDFF		No	EDFF									Weight	Weight
Study	Total	Mean	SD	Total	Mean	SD		Mean	Diffe	rence		MD	98	5%-CI	(fixed)	(random)
Bonello 2013	38	52.75	1.50	110	52.75	2.17			#	ł		0.00	[-0.63;	0.63]	17.8%	11.7%
Helbing 1996	13	51.00	11.00	5	54.00	7.00	3			+		-3.00	[-11.57;	5.57]	0.1%	4.8%
Kordybach-Prokopiuk 2018	16	47.40	11.10	67	46.50	7.70		-	<u></u>	+		0.90	[-4.84;	6.64]	0.2%	7.1%
Kutty 2018	122	51.75	1.67	227	46.75	0.17				+		5.00	[ 4.70;	5.30]	79.1%	11.8%
Lee 2013	33	48.70	8.20	17	45.90	11.90		-	-	+	_	2.80	[-3.51;	9.11]	0.2%	6.6%
Mercer-Rosa 2018	77	60.00	8.00	11	61.00	5.00		_	-	- 1		-1.00	[-4.45;	2.45]	0.6%	9.5%
Mori 2017	23	49.20	6.60	39	50.30	8.40		-	-	- 1		-1.10	[-4.87;	2.67]	0.5%	9.2%
Munkhammar 2013	16	49.00	8.00	15	54.00	6.00	-					-5.00	[-9.96;	-0.04]	0.3%	7.9%
Samyn 2013	12	59.00	4.33	17	59.50	6.00		-	-	-i		-0.50	[-4.26;	3.26]	0.5%	9.2%
Sani 2020	18	35.20	5.50	12	36.20	7.60		-		-		-1.00	[-5.99;	3.99]	0.3%	7.9%
Tominaga 2021	23	37.56	9.85	23	45.00	10.00			-	1		-7.44	[-13.18;	-1.70]	0.2%	7.1%
van den Berg 2007	24	49.00	6.00	12	49.00	9.00				+		0.00	[-5.63;	5.63]	0.2%	7.2%
Fixed-effects	415			555						4		3.91	[ 3.65;	4.18]	100.0%	
<b>Random-effects</b> Heterogeneity: $I^2 = 96\%$ , $p < 0$	.001						<b></b>	-	+	-		-0.56	[-2.64;	1.53]		100.0%
Test for overall effect (fixed eff Test for overall effect (random	ect): z effects	= 29.02 s): t <sub>11</sub> =	(p < 0. -0.59 (j	001) p = 0.5	70)		-10	-5	0	5	10					

## C. RVEDP (mmHg)

		E	DFF		No E	DFF				Weight	Weight
Study	Total	Mean	SD	Total	Mean	SD	Mean Difference	MD	95%-CI	(fixed)	(random)
Apitz 2010	8	10.40	1.00	17	10.40	0.60	— <b>—</b> []	0.00	[-0.75; 0.75]	45.5%	29.1%
Maskatia 2013	77	9.30	4.80	101	7.50	2.10		1.80	[0.65; 2.95]	19.4%	24.6%
Mori 2017	23	10.00	2.00	39	8.00	2.00		2.00	[0.97; 3.03]	24.1%	25.9%
Tominaga 2021	23	9.25	2.57	23	8.00	2.70		1.25	[-0.27; 2.77]	11.0%	20.3%
Fixed-effects	131			180				0.97	[0.46; 1.47]	100.0%	
Random-effects	3							1.22	[-0.29; 2.72]		100.0%
Heterogeneity: $I^2$ =	= 76%, L	0 = 0.00	6								
Test for overall eff	ect (fixe	d effect	): z = :	3.75 (p	< 0.001	) .	3 -2 -1 0 1 2 3				

Test for overall effect (random effects):  $t_3 = 2.56$  (p = 0.083)

## D. RVESP (mmHg)

Study	Total	Mean	EDFF SD	Total	No Mean	EDFF SD	1	Mean D	ifferenc	e	MD	9	5%-CI	Weight (fixed)	Weight (random)
Apitz 2010 Kordybach-Prokopiuk 2018 Maskatia 2013 Mori 2017 Tominaga 2021	8 16 77 23 23	128.00 44.50 45.00 38.00 46.87	13.10 13.10 13.00 8.00 15.74	17 67 101 39 23	134.00 41.10 39.00 42.00 44.00	6.70 11.00 14.00 10.00 13.00		•		_	-6.00 3.40 6.00 -4.00 2.87	[-15.62; [-3.54; [ 2.01; [-8.53; [-5.47;	3.62] 10.34] 9.99] 0.53] 11.21]	6.9% 13.2% 39.9% 30.9% 9.1%	14.3% 19.2% 25.5% 24.4% 16.5%
<b>Fixed-effects</b> <b>Random-effects</b> Heterogeneity: $l^2 = 70\%$ , $p = 0$ Test for overall effect (fixed eff Test for overall effect (random	147 0.010 fect): z	= 1.14 (µ s): t <sub>4</sub> = 0.	o = 0.25 36 (p =	<b>247</b> 6) 0.738)			-15 -10	-5	0 5	10 1	<b>1.46</b> <b>0.82</b>	[-1.06; [-5.56;	3.98] 7.21]	100.0% 	 100.0%

**Figure S7. Forest plots.** CI, confidence interval; EDFF, end-diastolic forward flow; LVEDVi, left ventricular end-diastolic volume indexed; LVEF, left ventricular ejection fraction; LVESVi, left ventricular end-systolic volume indexed; LVSVi, left ventricular stroke volume indexed; MD, mean difference; SD, standard deviation.

## A. LVEDVi (mL/m<sup>2</sup>)

		EDFF	No	EDFF				Weight	Weight
Study	Total M	lean SD	Total Mear	n SD	Mean Difference	MD	95%-CI	(fixed)	(random)
Bonello 2013	38 7	4.00 5.70	110 73.75	5 3.17	: <b>+</b>	0.25	[-1.66; 2.16]	13.9%	34.9%
Helbing 1996	13 8	6.00 16.00	5 77.00	) 14.00	÷	- 9.00	[-6.04; 24.04]	0.2%	7.4%
Kutty 2018	122 8	32.08 3.05	227 87.05	5 4.20	+	-4.97	[-5.74; -4.21]	85.2%	36.8%
Lee 2013	33 8	3.90 15.20	17 79.40	21.10		4.50	[-6.79; 15.79]	0.4%	11.4%
Mori 2017	23 9	4.00 26.00	39 88.00	23.00	<u> </u>	6.00	[-6.85; 18.85]	0.3%	9.5%
Fixed-effects Random-effects	229		398			-4.15	[-4.86; -3.44] [-6.33: 6.34]	100.0%	 100.0%
Heterogeneity: I <sup>2</sup> = Test for overall effe Test for overall effe	88%, p < ect (fixed e ect (randor	< 0.001 effect): z = -1 m effects): t <sub>4</sub>	1.45 (p < 0.00 = 0.00 (p = 0	01) - ).998)	20 -10 0 10 2	0	[-0.00, 0.04]	-	100.070

## B. LVESVi (mL/m<sup>2</sup>)

Study	EDF Total Mean SI	F No ED D Total Mean	SD	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)
Kutty 2018 Lee 2013	122 34.00 1.8 33 33.90 7.8	3 227 37.00 2 3 17 32.50 10	.47 .38	<b>•</b>	-3.00 - 1.40	[-3.46; -2.54] [-4.22; 7.02]	99.3% 0.7%	71.1% 28.9%
Fixed-effects Random-effects Heterogeneity: $I^2$ = Test for overall effect Test for overall effect	<b>155</b> 57%, <i>p</i> = 0.126 ect (fixed effect): <i>z</i> = ect (random effects)	<b>244</b> -12.80 (p < 0.001) t t <sub>1</sub> = -0.87 (p = 0.5	-( 46)	-6 -4 -2 0 2 4 6	-2.97 -1.73	[-3.43; -2.52] [-27.07; 23.62]	100.0%	 100.0%

## C. LVSVi (mL/m<sup>2</sup>)

		E	DFF		No E	DFF								Weight	Weight
Study	Total	Mean	SD	Total	Mean	SD		Mear	n Diffe	rence		MD	95%-CI	(fixed)	(random)
Bonello 2013	38	46.50	2.33	110	46.75	2.50			-	_		-0.25	[-1.13; 0.63]	21.3%	47.7%
Kutty 2018	122	47.42	1.92	227	49.45	2.33	-					-2.03	[-2.48; -1.57]	78.7%	52.3%
Fixed-effects	160			337			-					-1.65	[-2.05; -1.24]	100.0%	
Random-effects												-1.18	[-12.44; 10.09]		100.0%
Heterogeneity: I <sup>2</sup> =	92%, p	< 0.00	1												
Test for overall effe	ect (fixed	d effect)	: z = -	7.99 (p	< 0.00 33 (p =	1) 0 411	-2	-1	0	1	2				

## D. LVEF (%)

			EDFF		No	EDFF				Weight	Weight
Study	Total	Mean	SD	Total	Mean	SD	Mean Difference	MD	95%-CI	(fixed)	(random)
Ahmad 2012	58	57.30	7.20	54	57.20	7.50		0.10	[-2.63; 2.83]	1.3%	10.8%
Bonello 2013	38	63.50	2.00	110	64.50	1.70	-	-1.00	[-1.71; -0.29]	18.8%	23.1%
Choi 2008	15	66.80	4.30	28	67.72	3.38	<b>+</b>	-0.92	[-3.43; 1.59]	1.5%	11.8%
Helbing 1996	13	49.00	12.00	5	56.00	11.00		-7.00	[-18.64; 4.64]	0.1%	1.0%
Kutty 2018	122	58.25	1.67	227	57.25	1.50	<b>1</b>	1.00	[ 0.65; 1.35]	75.5%	24.6%
Lee 2013	33	59.50	6.52	17	59.60	8.17	<u> </u>	-0.10	[-4.58; 4.38]	0.5%	5.5%
Mori 2017	23	59.10	6.60	39	57.40	7.10	_ <u>+</u> +	1.70	[-1.80; 5.20]	0.8%	7.9%
Samyn 2013	12	61.25	3.83	17	63.25	3.83		-2.00	[-4.83; 0.83]	1.2%	10.3%
Tominaga 2021	23	49.70	9.30	23	49.00	7.00	<u>}</u>	0.70	[-4.06; 5.46]	0.4%	5.0%
Fixed-effects	337			520				0.54	[ 0.23; 0.85]	100.0%	
Heterogeneity: $l^2 =$	74% 0	< 0.00	1					-0.20	[-1.20, 0.07]		100.076
Test for overall effe	ct (fixed	d effect	z = 3	44 (n <	0.001		15 10 5 0 5 10 15				

Test for overall effect (fixed effect): z = 3.44 (p < 0.001)Test for overall effect (fixed effect): z = 3.44 (p < 0.001)

-15 -10 -5 0 5 10 15

**Figure S8. Forest plots.** CI, confidence interval; EDFF, end-diastolic forward flow; MD, mean difference; RAAi, right atrial area indexed; RAVi, right atrial volume indexed; SD, standard deviation.

## A. RAAi (cm²/m²)

Study	Total	E Mean	DFF SD	Total	No E Mean	DFF SD		Mean	Diffe	rence		MD	95%-CI	Weight (fixed)	Weight (random)
Ahmad 2012 Kutty 2018	58 122	10.60 13.50	3.40 0.70	54 227	8.90 12.95	1.90 0.77					•	- 1.70 0.55	[ 0.69; 2.71] [ 0.39; 0.71]	2.4% 97.6%	40.2% 59.8%
<b>Fixed-effects</b> <b>Random-effects</b> Heterogeneity: $l^2$ = Test for overall effect	<b>180</b> 79%, <i>p</i> ect (fixe	o = 0.02 d effect	8 ): z = 1	<b>281</b> 7.19 (p	< 0.001	)	-2	-1	0	+     	2	0.58 1.01	[ 0.42; 0.74] [-6.15; 8.18]	100.0%	 100.0%

## B. RAVi (mL/m<sup>2</sup>)

Study	Total	Mean	EDFF SD	Total	No Mean	EDFF SD		Mean	Diffe	rence		MD	95%-0	Weight (fixed)	Weight (random)
Kutty 2018 Luijnenburg 2013 Tominaga 2021	122 31 23	42.42 58.00 83.52	1.92 10.00 18.30	227 20 23	42.08 52.00 70.00	3.65 9.00 20.00			+	+		0.35 6.00 13.52	[ -0.23; 0.9 [ 0.71; 11.2 [ 2.44; 24.6	3] 98.5% 3] 1.2% 3] 0.3%	45.8% 34.9% 19.3%
Fixed-effects Random-effects Heterogeneity: $I^2$ = Test for overall effect Test for overall effect	<b>176</b> 79%, p ct (fixe ct (ran	o = 0.00 d effect) dom effe	8 ): z = 1. ects): <i>t</i> ;	270 53 (p = 2 = 1.40	: 0.125) ) (p = 0.	297)	-20	-10	0	10	20	0.45 4.86	[ -0.13; 1.03 [-10.11; 19.84	i] 100.0% i]	 100.0%

**Figure S9. Forest plots.** CI, confidence interval; EDFF, end-diastolic forward flow; MD, mean difference; SD, standard deviation.

Study	Total	Mean	EDFF SD	Total	No Mean	EDFF SD	Mean Differenc	e	MD	95%-CI	Weight (fixed)	Weight (random)
Ahmad 2012	58	76.00	19.00	54	76.00	12.00	1 - <mark></mark> -	0	.00 [-5.84	4; 5.84]	26.1%	12.3%
Cardoso 2003	19	72.20	15.25	11	72.35	20.30	÷ •	-0	.15 [-13.97	; 13.67]	4.7%	9.1%
Cullen 1995	9	40.95	17.60	9	83.75	23.00	I	-42	.80 [-61.72	-23.88]	2.5%	7.1%
Gatzoulis 1995	20	45.65	13.10	17	57.65	53.60		-12	.00 [-38.12	; 14.12]	1.3%	5.0%
Helbing 1996	13	60.00	14.00	6	65.00	12.00		-5	.00 [-17.2	5; 7.25]	5.9%	9.7%
Munkhammar 1998	13	60.00	13.00	34	60.00	13.00		0	.00 [-8.3	1; 8.31]	12.9%	11.4%
Norgard 1998 (late restriction)	10	70.00	16.00	22	80.00	20.00		-10	.00 [-22.9]	7; 2.97]	5.3%	9.4%
Rathore 2006	52	70.50	7.50	28	88.00	14.00		-17	.50 [-23.07	; -11.93]	28.7%	12.3%
Sachdev 2006	24	70.98	19.90	26	96.90	23.40		-25	.92 [-37.93	; -13.91]	6.2%	9.8%
Samyn 2013	12	65.70	16.90	17	68.80	17.30		-3	.10 [-15.7	1; 9.51]	5.6%	9.6%
Vukomanovic 2006	18	207.81	51.45	42	243.38	61.95	•	-35	.57 [-65.83	3; -5.31]	1.0%	4.1%
Fixed-effects	248			266			•	-9	.19 [-12.17	; -6.20]	100.0%	
Random-effects								11	.59 [-20.85	; -2.32]		100.0%
Heterogeneity: $l^2 = 79\%$ , $p < 0.0$	001							1 1				
Test for overall effect (fixed effect	ct): z = -	6.04 (p <	< 0.001)	)			60 -40 -20 0 20	40 60				
Test for overall effect (random e	ffects):	$t_{10} = -2.7$	'9 (p =	0.019)								

#### A. E wave velocity at the tricuspid valve (cm/sec)

## B. E wave duration at the tricuspid valve (msec)



### C. E wave deceleration at the tricuspid valve (msec)

Study	Total	Mean	EDFF SD	Total	No Mean	EDFF SD		Mean	Differe	nce		MD	ç	5%-CI	Weight (fixed)	Weight (random)
Cullen 1995	9	96.75	50.60	9	126.00	15.00		+	#			-29.25	[-63.73	5.23]	0.5%	10.0%
Gatzoulis 1995	20	123.15	31.55	17	145.25	35.65						-22.10	[-43.97;	-0.23]	1.2%	13.7%
Gatzoulis 1998	36	120.80	31.00	52	120.10	29.50			++-			0.70	[-12.22;	13.62]	3.3%	16.2%
Helbing 1996	13	164.00	47.00	6	141.00	62.00		-	<u>+</u> +++++++++++++++++++++++++++++++++++			23.00	[-32.80;	78.80]	0.2%	5.9%
Kutty 2018	122	180.30	11.80	277	185.75	12.50			-			-5.45	[ -8.01;	-2.89]	84.4%	17.9%
Munkhammar 1998	13	140.20	36.20	34	129.80	30.00			+++-			10.40	[-11.71;	32.51]	1.1%	13.6%
Rathore 2006	52	99.40	18.00	28	139.65	16.20		-				-40.25	[-47.99;	-32.51]	9.2%	17.3%
Sachdev 2006	24	86.90	21.70	26	151.40	152.60		•				-64.50	[-123.80;	-5.20]	0.2%	5.4%
Fixed-effects	289			449					0			-8.62	[-10.97;	-6.27]	100.0%	
Random-effects									÷			-14.51	[-34.45;	5.43]		100.0%
Heterogeneity: $I^2 = 9^{\circ}$	1%, p <	0.001						1					11			
Test for overall effect	(fixed e	effect): z	= -7.19	(p < 0.	001)		-100	-50	0	50	100					
Test for overall effect	(rando	m effects	s): t7 = .	-1.72 (p	= 0.129	)										

**Figure S10. Forest plots.** CI, confidence interval; EDFF, end-diastolic forward flow; MD, mean difference; SD, standard deviation.

#### A. A wave velocity at the tricuspid valve (cm/sec)

			EDFF		No	EDFF									Weight	Weight
Study	Total	Mean	SD	Total	Mean	SD		Mean	Differ	ence		MD	95	%-CI	(fixed)	(random)
Ahmad 2012	58	50.00	15.00	54	50.00	12 00			-			0.00	[-5.01	5 0 11	17.7%	13.0%
Cardoso 2003	19	62.05	12.20	11	71.40	12.50	_		-11			-9.35	[-18.55:	-0.151	5.2%	9.9%
Cullen 1995	9	41.50	18.85	9	51.00	16.80				-		-9.50	[-26.00;	7.001	1.6%	5.7%
Gatzoulis 1995	20	28.70	21.34	17	27.46	7.62			-	_		1.24	[-8.79; 1	1.27]	4.4%	9.3%
Helbing 1996	13	50.00	8.00	6	50.00	10.00		-		-		0.00	[-9.11;	9.11]	5.4%	10.0%
Munkhammar 1998	13	48.00	11.00	34	49.00	15.00			-	-		-1.00	[-8.82;	6.82]	7.3%	10.9%
Norgard 1998 (late restriction)	10	50.00	20.00	22	60.00	16.00			÷.			-10.00	[-24.08;	4.08]	2.2%	6.8%
Rathore 2006	52	70.00	8.00	28	60.00	6.50						10.00	[ 6.76; 1	[3.24]	42.2%	14.0%
Sachdev 2006	24	71.76	7.90	26	75.67	14.80		-				-3.91	[-10.42;	2.60]	10.5%	11.9%
Samyn 2013	12	45.00	15.10	17	45.00	15.60		-	•			0.00	[-11.31; 1	1.31]	3.5%	8.5%
Fixed-effects	230			224					-			2.92	[ 0.82;	5.03]	100.0%	
Random-effects							_	-	-			-1.20	[ -5.68;	3.27]		100.0%
Heterogeneity: $I^2 = 76\%$ , $p < 0.0$	D1						1	1	1	1						
Test for overall effect (fixed effec	t): z = 2	2.72 (p	= 0.007	)			-20	-10	0	10	20					
Test for overall effect (random ef	fects):	t 9 = -0.1	61 (p =	0.558)												

### B. A wave duration at the tricuspid valve (msec)



### C. E/A at the tricuspid valve

		E	DFF		No E	DFF				Weight	Weight
Study	Total	Mean	SD	Total	Mean	SD	Mean Difference	MD	95%-CI	(fixed)	(random)
Ahmad 2012	58	1.52	127	45	1.52	1 00	\$_ <b>_</b>	0.00	[-0 44: 0 44]	3.0%	6.3%
Cardoso 2003	19	1.20	0.25	11	1.00	0.30		0.20	[-0.01; 0.41]	13.2%	13.0%
Gatzoulis 1998	36	1.70	0.49	56	1.84	0.56		-0.14	[-0.36: 0.08]	12.3%	12.7%
Helbing 1996	13	1.19	0.22	6	1.36	0.32		-0.17	[-0.45; 0.11]	7.3%	10.3%
Kutty 2018	122	1.85	0.13	277	1.85	1.13		0.00	[-0.14; 0.14]	31.9%	16.0%
Norgard 1998 (late restriction)	10	1.40	0.80	22	1.33	1.25	·	- 0.07	[-0.65; 0.79]	1.1%	2.9%
Sachdev 2006	24	0.98	0.17	26	1.33	0.49		-0.35	[-0.55; -0.15]	14.5%	13.4%
Samyn 2013	12	1.57	0.59	17	1.69	0.66		-0.12	[-0.58; 0.34]	2.8%	5.9%
Sani 2020	18	1.20	0.50	12	1.20	0.50	<b>+</b>	0.00	[-0.37; 0.37]	4.4%	7.9%
Vukomanovic 2006	18	1.49	0.38	42	1.88	0.58		-0.39	[-0.64; -0.14]	9.4%	11.5%
Fixed-effects	330			514			***	-0.09	[-0.17; -0.02]	100.0%	
Random-effects Heterogeneity: $l^2 = 60\%$ , $p = 0.0$	08							-0.11	[-0.25; 0.03]		100.0%
Test for overall effect (fixed effec	t): z = -	2.40 (p	= 0.0	16)			-0.5 0 0.5				
Test for overall effect (random ef	fects):	t9 = -1.7	72 (p =	= 0.119	)						

**Figure S11. Forest plots.** CI, confidence interval; EDFF, end-diastolic forward flow; MD, mean difference; SD, standard deviation.

## A. E' at the tricuspid valve (cm/sec)

Study	Total	E Mean	SD	Total	No E Mean	SD SD		Mea	n Differer	nce	M	9	5%-CI	Weight (fixed)	Weight (random)
Ahmad 2012	58	11.00	2.00	54	11.00	3.00					0.0	0 [-0.95	; 0.95]	81.7%	58.4%
Samyn 2013	12	14.60	2.60	16	12.40	2.80				•	- 2.2	0 [ 0.19	; 4.21]	18.3%	41.6%
Fixed-effects	70			70					1		0.4	0 [-0.46	1.26]	100.0%	-
Random-effects	700/	0.05	~	-			-			-	0.9	1 [-12.86;	14.69]	-	100.0%
Heterogeneity: /- =	13%, p	0 = 0.05	3	02/2	- 0.250		÷.				4				
Test for overall effe	ect (ran	dom effe	ects):	$t_1 = 0.8$	= 0.358 34 (p = 1	0.554)	-4	-2	U	2	4				

# B. A' at the tricuspid valve (cm/sec)

		E	DFF		No E	DFF								Weight	Weight
Study	Total	Mean	SD	Total	Mean	SD		Mean	Diffe	rence		MD	95%-CI	(fixed)	(random)
Ahmad 2012	58	5.00	2.00	54	5.00	1.00		-				0.00	[-0.58; 0.58]	86.0%	86.0%
Samyn 2013	12	7.00	2.20	17	7.00	1.50 -			+			- 0.00	[-1.43; 1.43]	14.0%	14.0%
Fixed-effects	70			71					÷			0.00	[-0.54; 0.54]	100.0%	
Random-effects												0.00	[0.00; 0.00]		100.0%
Heterogeneity: $I^2 =$	0%, p	= 1.000						1		1					
Test for overall effe	ct (fixed	d effect)	: z = (	0.00 (p	= 1.000	))	-1	-0.5	0	0.5	1				
Test for overall effe	ct (rand	dom effe	ects):	$t_1 = NA$	A(p = N	A)									

## C. E/E' at the tricuspid valve

		E	DFF		No E	DFF					Weight	Weight
Study	Total	Mean	SD	Total	Mean	SD	Mean Differe	nce	MD	95%-CI	(fixed)	(random)
Ahmad 2012	58	7.00	2.50	54	7.80	3.20			-0.80	[-1.87; 0.27]	53.4%	53.4%
Samyn 2013	12	4.70	1.70	17	5.70	1.30			-1.00	[-2.14; 0.14]	46.6%	46.6%
Fixed-effects	70			71					-0.89	[-1.67; -0.11]	100.0%	
Random-effects									-0.89	[-2.16; 0.37]		100.0%
Heterogeneity: $I^2 =$	0%, p	= 0.802					1 1 1	1 1				
Test for overall effe	ect (fixe	d effect	): z = .	2.24 (	= 0.02	5)	-2 -1 0	1 2	2			
Test for overall effe	ect (ran	dom eff	ects):	$t_1 = -8.$	95 (p =	0.071)						

**Figure S12. Forest plots.** CI, confidence interval; EDFF, end-diastolic forward flow; MD, mean difference; OR, odds ratio; PR, pulmonary regurgitation; SD, standard deviation.

#### A. Moderate to severe PR

Study	Events	EDFF Total E	No Events	EDFF Total	Odds Ratio	OR	95%-CI	Weight (fixed)	Weight (random)
Ahmad 2012 Mori 2017 Xu 2014	39 12 19	58 23 30	34 18 28	54 39 50		1.21 - 1.27 - 1.36	[0.55; 2.63] [0.45; 3.57] [0.54; 3.44]	45.0% 24.9% 30.1%	44.1% 25.0% 30.9%
<b>Fixed-effects</b> <b>Random-effects</b> Heterogeneity: <i>J</i> <sup>2</sup> = Test for overall eff Test for overall eff	<b>s</b> = 0%, p = 0 fect (fixed e fect (randor	<b>111</b> 0.982 effect): z m effects	= 0.90 ( s): t <sub>2</sub> = 6	<b>143</b> p = 0.366 .75 (p = 0	0.5 1 2	1.27 1.27	[0.76; 2.13] [1.09; 1.48]	100.0% 	 100.0%

## B. PR fraction (%)

Study	Total	Maan	EDFF	Total	No	EDFF	Maan Difference	MD	05% CI	Weight	Weight
Study	lotai	wean	50	Total	mean	20	Mean Difference	MD	95%-CI	(fixed)	(random)
Apitz 2010	8	38.90	2.90	17	28.60	5.20	<del></del> {	10.30	[7.11; 13.49]	8.1%	19.6%
Kordybach-Prokopiuk 2018	16	29.90	14.00	67	23.50	17.50	+++	6.40	[-1.64; 14.44]	1.3%	7.3%
Kutty 2018	122	38.38	4.42	277	25.75	5.38		12.62	[11.62; 13.63]	81.1%	27.3%
Lee 2013	33	44.20	8.90	17	36.70	12.10		7.50	[1.00; 14.00]	1.9%	9.9%
Luijnenburg 2013	31	36.00	13.00	20	15.00	17.00		21.00	[12.26; 29.74]	1.1%	6.4%
Munkhammar 2013	16	45.00	9.00	15	23.00	19.00	<del>€ +</del>	22.00	[11.42; 32.58]	0.7%	4.7%
Samyn 2013	12	44.75	5.50	17	28.00	8.00		16.75	[11.84; 21.66]	3.4%	13.7%
van den Berg 2007	24	33.25	9.17	12	21.50	8.30		11.75	[ 5.79; 17.71]	2.3%	11.0%
Fixed-effects	262			442				12 54	[11 63: 13 44]	100.0%	
Random-effects	202							12.66	[ 8.91; 16.41]		100.0%
Heterogeneity: $I^2 = 56\%$ , $p = 0$	0.025								•		
Test for overall effect (fixed eff	fect): z	= 27.07	(p < 0.	001)			-30 -20 -10 0 10 20 30				
Test for overall effect (random	effects	s): t <sub>7</sub> = 7	7.99 (p	< 0.001	I)						

# C. PR duration (msec)

Study	Total	Mean	EDFF SD	Total	No Mean	EDFF SD	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)
Gatzoulis 1995 Lee 2013 Mercer-Rosa 2018 Munkhammar 1998 Norgard 1998 (early restriction) Norgard 1998 (late restriction) Sachdev 2006	20 33 77 13 16 10 24	300.20 325.60 42.50 253.30 171.00 219.80 166.60	65.40 77.10 2.67 41.90 76.00 52.00 79.50	18 17 11 34 18 22 26	442.10 321.80 31.25 353.00 174.00 254.60 233.30	54.10 55.70 2.83 71.80 39.00 40.60 86.80		-141.90 3.80 11.25 -99.70 -3.00 -34.80 -66.70	[-179.93; -103.87] [-33.52; 41.12] [ 9.47; 13.03] [-132.88; -66.52] [-44.37; 38.37] [-71.22; 1.62] [-112.80; -20.60]	0.2% 0.2% 98.7% 0.3% 0.2% 0.2% 0.1%	14.1% 14.2% 15.6% 14.4% 13.9% 14.2% 13.5%
<b>Fixed-effects</b> <b>Random-effects</b> Heterogeneity: $l^2 = 95\%$ , $p < 0.00^{\circ}$ Test for overall effect (fixed effect) Test for overall effect (random effect)	<b>193</b> 1 2 z = 1 ects): <i>t</i>	1.49 (p < s = -2.11	0.001) (p = 0.0	<b>146</b>			-150 -50 0 50 100 150	10.34 -46.57	[ 8.58; 12.11] [-100.46; 7.32]	100.0% 	 100.0%

**Figure S13. Forest plots.** BNP, brain natriuretic peptide; CI, confidence interval; EDFF, enddiastolic forward flow; MD, mean difference; NT-proBNP, N-terminal pro hormone brain natriuretic peptide; OR, odds ratio; SD, standard deviation.

## A. QRS duration (msec)

Study	Total	Mean	EDFF SD	Total	No Mean	EDFF SD	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)
Aburawi 2014	9	123.00	29.00	11	114.00	25.00		9.00	[-15.03; 33.03]	0.3%	3.9%
Ahmad 2012	58	148.00	29.00	54	139.00	23.00	<del>    • -</del> -	9.00	[-0.66; 18.66]	2.0%	6.5%
Apitz 2010	8	148.70	10.30	17	158.50	5.90		-9.80	[-17.47; -2.13]	3.2%	6.8%
Bonello 2013	38	146.00	27.00	110	147.00	23.00		-1.00	[-10.60; 8.60]	2.0%	6.5%
Cardoso 2003	19	130.00	20.00	11	100.00	40.00	l	30.00	[ 4.71; 55.29]	0.3%	3.7%
Eroglu 1999	25	140.00	18.00	19	156.00	24.00	<b>_</b> _	-16.00	[-28.89; -3.11]	1.1%	5.9%
Gatzoulis 1998	36	123.30	16.60	56	125.40	18.50		-2.10	[-9.37; 5.17]	3.5%	6.9%
Kordybach-Prokopiuk 2018	16	132.90	33.70	67	154.60	21.80		-21.70	[-39.02; -4.38]	0.6%	5.1%
Kutty 2018	122	138.50	7.70	227	143.50	5.70	•••	-5.00	[-6.55; -3.45]	76.7%	7.4%
Lee 2013	33	137.60	19.30	17	136.90	28.10	— <u><u></u><u></u></u>	0.70	[-14.19; 15.59]	0.8%	5.5%
Mori 2017	23	137.00	32.00	39	129.00	41.00	- <u>  </u>	8.00	[-10.35; 26.35]	0.6%	4.9%
Norgard 1998 (early restriction)	16	71.90	17.30	18	70.60	12.20	<b> </b>	1.30	[-8.88; 11.48]	1.8%	6.4%
Norgard 1998 (late restriction)	10	116.20	15.20	22	117.40	12.90		-1.20	[-12.05; 9.65]	1.6%	6.3%
Samyn 2013	12	143.75	15.83	17	85.00	16.67	i	- 58.75	[46.79; 70.71]	1.3%	6.1%
Sani 2020	18	156.70	13.70	12	142.50	14.80		14.20	[ 3.70; 24.70]	1.7%	6.3%
Sani 2020	18	156.70	13.70	12	142.50	14.80	<b>↓</b>	14.20	[ 3.70; 24.70]	1.7%	6.3%
Tominaga 2021	23	152.38	21.83	23	145.00	29.00		7.38	[-7.45; 22.21]	0.8%	5.5%
-											
Fixed-effects	484			732			*	-2.90	[-4.26; -1.54]	100.0%	
Random-effects								4.98	[-4.30; 14.26]		100.0%
Heterogeneity: $I^2 = 90\%, p < 0.00$	1										
Test for overall effect (fixed effect)	): z = -4	.18 (p <	0.001)				-60 -40 -20 0 20 40 60				

Test for overall effect (random effects):  $t_{16} = 1.14$  (p = 0.272)

# B. BNP (pg/mL)

	EC	DFF	No EDFF				Weight	Weight
Study	Total Mean	SD Total Me	an SD	Mean Difference	MD	95%-CI	(fixed)	(random)
Apitz 2010 Mori 2017 Samyn 2013	8 37.60 6 23 29.10 26 12 42.50 20	5.50         17         28.           5.20         39         22.           0.67         17         17.	60 5.20 00 30.00 50 6.33		9.00 7.10 - 25.00	[ 3.86; 14.14] [-7.16; 21.36] [ 12.92; 37.08]	76.3% 9.9% 13.8%	44.8% 25.5% 29.7%
<b>Fixed-effects</b> <b>Random-effects</b> Heterogeneity: $I^2$ = Test for overall effect Test for overall effect	<b>43</b> 67%, <i>p</i> = 0.049 cct (fixed effect): <i>z</i> cct (random effects)	<b>73</b> = 4.81 (p < 0.0 s): t <sub>2</sub> = 2.45 (p	01) = 0.134)	-30 -20 -10 0 10 20 30	11.02 - 13.26	[ 6.53; 15.51] [-10.05; 36.58]	100.0% 	 100.0%

# C. NT-proBNP (pg/mL)

			EDFF		N	D EDFF				Weight	Weight
Study	Total	Mean	SD	Total	Mean	SD	Mean Difference	MD	95%-CI	(fixed)	(random)
Kordybach-Prokopiuk 2018	16	433.00	686.90	67	219.60	292.40	- <u> </u>	- 213.40	[-130.38; 557.18]	1.8%	1.8%
Luijnenburg 2013	31	144.14	90.09	20	81.08	81.08		63.06	[ 15.43; 110.69]	93.0%	93.0%
Mori 2017	21	158.30	175.50	34	183.80	555.10		-25.50	[-226.62; 175.62]	5.2%	5.2%
Fixed-effects	68			121			÷	61.12	[ 15.19; 107.06]	100.0%	
Random-effects								61.12	[-25.40; 147.65]		100.0%
Heterogeneity: $I^2 = 0\%$ , $p = 0$ .	479										
Test for overall effect (fixed eff	fect): z	= 2.61 (	o = 0.009	)			-400 -200 0 200 400				
Test for overall effect (random	effects	s): t <sub>2</sub> = 3	04 (p = 0)	0.093)							

**Figure S14. Forest plots.** CI, confidence interval; EDFF, end-diastolic forward flow; MD, mean difference; OR, odds ratio; SD, standard deviation; VO2, oxygen consumption.

## A. Peak VO2 (%)

Study	Total	Mean	EDFF SD	Total	No Mean	EDFF SD	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)
Babu-Narayan 2012 Bonello 2013 Gatzoulis 1995 Lee 2013 Mercer-Rosa 2018 Samyn 2013 van den Berg 2007	27 38 17 33 63 12 24	85.00 76.05 100.90 70.30 80.00 79.00 89.00	20.00 4.17 13.80 11.50 17.00 11.30 11.00	37 110 12 17 23 17 12	70.00 75.50 82.50 54.70 73.00 68.50 97.00	15.00 4.30 10.10 12.90 18.00 7.67 17.00		15.00 0.55 18.40 15.60 7.00 10.50 -8.00	[ 6.04; 23.96] [ -1.00; 2.10] [ 9.70; 27.10] [ 8.32; 22.88] [ -1.47; 15.47] [ 3.14; 17.86] [-18.58; 2.58]	2.5% 82.9% 2.6% 3.8% 2.8% 3.7% 1.8%	13.5% 17.3% 13.7% 14.6% 13.8% 14.6% 12.4%
<b>Fixed-effects</b> <b>Random-effects</b> Heterogeneity: $I^2 = 88$ Test for overall effect Test for overall effect	<b>214</b> %, <i>p</i> < (fixed e (randor	0.001 ffect): z = n effects	= 3.25 () ): t <sub>6</sub> = 2	<b>228</b> p = 0.0 .43 (p :	01) = 0.051)	)	-20 -10 0 10 20	2.34 8.43	[ 0.93; 3.75] [-0.05; 16.92]	100.0% 	 100.0%

## B. Peak VO2 (mL/kg/min)

		E	DFF		No E	DFF	1 Marcal Antonio Marcal			Weight	Weight
Study	Total	Mean	SD	Total	Mean	SD	Mean Difference	MD	95%-CI	(fixed)	(random)
Bonello 2013	38	25.30	1.50	110	26.50	1.70		-1.20	[-1.77; -0.63]	26.1%	20.1%
Kutty 2018	122	27.73	1.58	277	24.35	1.87		3.38	[ 3.02; 3.73]	67.4%	20.2%
Mercer-Rosa 2018	63	34.00	8.00	23	29.00	7.00	)	5.00	[ 1.52; 8.48]	0.7%	15.8%
Rathore 2006	52	26.30	3.10	28	29.20	2.60	)	-2.90	[-4.18; -1.62]	5.2%	19.5%
van den Berg 2007	24	39.00	9.00	12	45.00	8.00	)	-6.00	[-11.78; -0.22]	0.3%	11.4%
Fixed-effects	317			462			4	1.85	[ 1.55; 2.14]	100.0%	
Random-effects								0.65	[-3.86; 5.15]		100.0%
Heterogeneity: $I^2 = 9$	8%, p	< 0.001					1 1 1 1				
Test for overall effect	t (fixed	effect):	z = 12	.36 (p	< 0.001	)	-10 -5 0 5 1	0			
Test for overall effec	t (rando	om effec	:ts): t5	= 0.37	(p = 0.	727)					

Figure S15. Publication bias analysis by funnel plot graphic. (A) transannular patch repair. (Begg and Mazumdar's test: p=0.025, Egger's test: p=0.002). (B) right atrial volume indexed. (Begg and Mazumdar's test: p=0.117, Egger's test: p=0.014). (C) pulmonary regurgitation fraction. (Begg and Mazumdar's test: p=0.453, Egger's test: p=0.038). (D) A wave velocity at the tricuspid valve. (Begg and Mazumdar's test: p=0.655, Egger's test: p=0.005).

